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Abstract 
This study explored the effects of number of intrathecal chemotherapies and time off 
therapy on cognitive, achievement, and neuropsychological functioning of post treatment 
children with Acute Lymphocytic Leukemia (ALL). Participants consisted of sixteen sibling 
pairs between the ages of eight and fourteen who were grouped into the high or low group for 
number of intrathecal chemotherapies (IT), and then regrouped for high or low time off therapy 
(TOT). Participants were administered a battery of cognitive, achievement, and 
neuropsychological tests. Matched sibling difference scores from these tests were analyzed. 
Results found that children with ALL performed in the average range, although below their 
healthy siblings in some domains, indicating that treatments appear to be doing less harm than 
anticipated from the past literature. Results indicate that on reading composite (comprehension 
and pseudoword reading) and math reasoning the high IT  children with ALL, when compared 
with low IT  children with ALL, performed more poorly than their healthy siblings. A large 
effect size for intelligence quotient indicated that high IT  children with ALL, when compared 
with low IT  children with ALL, performed more poorly than their healthy siblings. Large effect 
sizes also were noted for time off therapy (TOT) for reading composite and math reasoning, with 
the high TOT  children with ALL performing more poorly than the low TOT children with ALL, 
relative to their healthy siblings. Nevertheless, there is cause for optimism.  
This study replicated prior research on the effects of high number of intrathecal 
chemotherapies on the intellectual, reading, and math performance of children with ALL, with 
late effects becoming most apparent at five or more years post therapy.  However, post hoc 
analyses cautioned that these results should be interpreted conservatively, given the study’s 
methodological limitations.  
  
 
  
 
 
 
Cognitive, Academic, and Neuropsychological Effects of Treatment 
For Childhood Acute Lymphocytic Leukemia 
By 
David S. Gordon 
 
B.A. Southern Connecticut State University, New Haven, CT, December, 1991 
M.S. Southern Connecticut State University, New Haven, CT, May, 1992 
 
 
 
Dissertation 
Submitted in partial fulfillment of the requirement for the degree of Doctor of Philosophy in 
Special Education Syracuse University  
 
Syracuse University 
August, 2016 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
Copyright © 2016 
 David S. Gordon
  
  
 
 
Acknowledgments 
I would never have been able to finish my dissertation without the guidance of my 
committee members, help from friends, and support from my family and wife. 
I would like to express my deepest gratitude to my advisor, Dr. Corinne Smith, for her 
never-ending patience, excellent guidance, and caring. She has provided me with the support to 
pursue this degree while still allowing me to figure out my own unique path.  
I would like to thank Dr. Benita Blachman and Dr. Laurence Lewandowski for guiding 
my research as committee members for the past several years and helping me to develop as a 
researcher, as well as Paul Preczewski for his endless assistance on the statistical aspects of this 
research and my personal growth in this area. 
I would also like to thank my parents. This dissertation is done in part as a fulfillment of 
one of my father’s dreams, who is a professor in every way with the exception of the letters after 
his name. This dissertation was only possible due to my mother, who advocated for my K-12 
education unwaveringly. Without her belief in me as a learner, college in any form would have 
been unattainable.  
I would like to especially thank my wife, Ruta Shah-Gordon, and my two daughters 
Anjali Shah Gordon and Kavita Shah Gordon. They were always there cheering me on and 
cheering me up, and they stood by me through the ups and downs of this process. Without their 
support and belief in me I would never have had the strength to try, fail, and try again. 
Finally, I dedicate this dissertation to all of the tremendous learners I worked with at 
Tomorrows Children’s Institute; in particular to Jordan and Frankie, who have helped to shape 
me as an educator and human being.
v 
 
 
Contents 
 
Chapters Page 
  
Acknowledgments ........................................................................ iv 
 Lists of Tables, Consent, and Institutional Review Board  
Forms…………………………………………………………..….v 
 
Chapter One: Introduction ...........................................................1 
 
Chapter Two: Literature Review .....................................………6 
Effects of Cranial-Spinal Radiation Treatment Compared to  
Systemic and Intrathecal Chemotherapy Treatment …………. 6 
Effects of Systemic and Intrathecal Chemotherapy 
Treatment……………………………………………………..10 
Time Off Therapy Effects of Systemic and Intrathecal  
Chemotherapy……….. ………………………………............15 
Brain Physiology Research on Post Therapy Children 
With ALL…………………………………….……………… 18  
Summary of Childhood ALL Neurocognitive  
and Achievement Research  …………………………………..22 
Current Study…...…………………………………………….24  
 
Chapter Three: Method  ..............................................................26 
Rationale for the Method  ........................................................  26 
Participants ..............................................................................  26 
Recruitment .............................................................................  29   
Measures .................................................................................  30   
Procedures  ..............................................................................  37 
Confidentiality ........................................................................  38 
Research Design and Statistical Analysis ................................39 
Assessment of Violation of Assumptions ..........................................41 
 
Chapter Four: Results  .................................................................44 
Descriptive Statistics ................................................................44 
Intelligence ........................................................................................................44 
Reading Composite ..................................................................46 
Math Reasoning .......................................................................47   
Three-Minute Writing ..............................................................49 
Inattention ...............................................................................  49 
Impulsivity ...............................................................................50 
Processing Speed ....................................................................  51 
Verbal Memory ........................................................................52 
Executive Functioning .............................................................53 
Parent Perception of Executive Functioning............................53 
Post Hoc Analysis……………………………………………54 
Summary .................................................................................  55 
v 
 
 
 
Chapter Five: Discussion .............................................................57   
Major Findings ............................................................................... 57   
Domain Specific Findings ................................................................. 59 
Limitations ...............................................................................61  
Implications of Findings ..........................................................64 
Suggestions for Future Research ..................................................... 65 
 
Appendices ....................................................................................70 
 
References………………………………………………………105 
Vita……...………………………………………………………119 
 
 
  
v 
 
 
List of Tables, Consent, and Institutional Review Board Forms 
 
Appendices:                  Page 
 
Appendix A  Table 1 Sibling Pair Demographic Data……... ……………….71  
  Table 2 Scatter Plot of Participant IT and TOT Groups...…..73 
  Table 3 Descriptive Statistics for Children with ALL  
and Healthy Sibling Groups…………………….…. 74 
  Table 4 Descriptive Statistics for High/Low IT and  
High/Low TOT Groups of Post Treatment  
Children with ALL ………………………………... 75  
  Table 5 Descriptive Statistics for High/Low IT and  
High/Low TOT Groups of Healthy Siblings….. …...76   
Table 6  Children with ALL: Mean Scores on. Significant, 
Large, and Medium Effect Measures.........................77 
Table 7 Healthy Siblings: Mean Scores on Significant. 
Large, and Medium Effect Measures.........................79 
   Table 8 Difference Score Statistical Analyses for  
   Number of Intrathecal Chemotherapy Treatments.....81 
   Table 9      Difference Score Statistical Analyses for  
                                                            Time off Therapy……………………………………82 
  Table 10    Wechsler Intelligence Scale for Children -   
Fourth Edition Subscale Scores…...….……………. 83 
  Table 11   Children with ALL: WISC-IV subscale  
                                                            Individual Scores........................................................84                                                          
  Table 12  Healthy Siblings: WISC-IV subscale  
                                                            Individual Scores ……………..…………………….85 
  Table 13     Sibling Pair Large Variability Data………………....86 
                                    Table 14 Sibling and Children with ALL Attention. 
Data: Reddick (2006)……………………………….88 
  
Appendix B  Consent Forms Hackensack University Medical Center …………..89 
Appendix C  Consent Forms Syracuse University ………………………….……95 
Appendix D  Institutional Review Board Hackensack University   
Medical Center …………………………………………………....102  
Appendix E  Institutional Review Board Syracuse University ............................104 
 
 
 
 
 
 
  
  
  
 
Cognitive, Academic, and Neuropsychological Effects of Treatment for  
Children with Acute Lymphocytic Leukemia 
Chapter 1: Introduction 
According to the American Cancer Society, approximately 10,380 children under the age 
of fifteen develop some form of cancer each year (American Cancer Society, 2016). In the 
United States there are approximately 60,000 survivors of childhood cancer under the age of 15 
(Siegel et al., 2012). Approximately 3,000 of these children are diagnosed with acute 
lymphocytic leukemia (ALL), the most common of all childhood cancers. ALL is also one of the 
most treatable childhood cancers, with current survivor estimates of 90% (American Cancer 
Society, 2016). However, treatment comes with a price, as approximately 40% of children with 
ALL experience a deficit in some aspect of neurocognitive functioning (Nathan et al., 2007).  
Leukemia is a cancer of the blood that causes rapid mitosis (cell division) of immature 
white blood cells.  This rapid mitosis causes the bone marrow to fill up quickly with the 
leukemia cells, leaving little room for platelets and red blood cells. These immature cells do not 
perform the function of normal, healthy white blood cells and place the child at risk for death due 
to overwhelming infection. The illness presents with bleeding, bruising, and anemia (Armstrong 
& Mulhern, 1999). Because blood moves throughout all organs of the body, leukemia is known 
to migrate into the central nervous system (CNS). Leukemia cells also are known to hibernate in 
the CNS. Historically, the prognosis for children with leukemia was very poor when receiving 
only systemic chemotherapies (chemotherapies given through intravenous injection, orally, or 
intramuscularly), as these treatments could not pass through the blood-brain barrier and enter the 
central nervous system. Survival rates increased when treatment protocols of the 1970s started to 
include CNS radiation treatment, giving lifesaving treatment directly into the central nervous 
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system. Therefore, all current leukemia treatment protocols require systemic chemotherapy and 
some form of therapy to terminate leukemia cells in the CNS, the blood stream, and bone 
marrow.  These treatment protocols include cranial-spinal radiation, intrathecal chemotherapy 
(chemotherapy treatments administered directly into the epidural space at the base of the spinal 
cord, via a spinal tap), or stem cell bone marrow transplant.  
Since the 1970s, researchers have examined the cognitive and educational impact of 
childhood cancer and treatments (see Armstrong, Blumberg, & Toledano, 1999; Campbell et al., 
2007; Peterson et al., 2008; Robinson et al., 2009). During the 1970s and early 1980s, most 
children with ALL received a treatment regimen consisting of cranial-spinal radiation, systemic 
chemotherapy (SC) (administered orally, intravenously, or intramuscularly), and intrathecal 
chemotherapy (IT) (Armstrong et al., 1999). These protocols were effective in curing 70 - 80% 
of children. However, a series of studies showed high toxicity levels caused by these treatments, 
resulting in considerable losses in intellectual, achievement, and information processing abilities.  
Meadows et al. (1981) conducted one of the first comprehensive studies regarding long-
term intellectual and achievement outcomes of post therapy children with ALL who received 
cranial-spinal radiation treatment. All participants (n = 31) in this study received baseline testing 
within the first month of diagnosis and, prior to receiving radiation therapy, they all tested in the 
average range of intelligence. Twenty-eight of the participants were tested again 12-34 months 
after treatment and eighteen were again tested three years later. Follow-up testing demonstrated 
that the majority of the participants demonstrated lower global intellectual and academic 
functioning than when first diagnosed. Participants with a baseline IQ between 86 – 109 
averaged an 8 point drop in IQ at the time of follow-up testing. Participants with a baseline IQ 
between 110 – 132 averaged a 23.5 point decrease at follow up testing. In addition, a significant 
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age effect showed greater relative delays in intellectual functioning for younger than older 
children. This was the first study to demonstrate that age at diagnosis coupled with cranial-spinal 
radiation therapy (CRT) played an important role in detrimental cognitive late effects.  
Following the influential work of Meadows et al. (1981), numerous studies in the 1980s 
and 1990s focused on the relationship between cranial-spinal radiation therapy and 
cognitive/achievement effects after children with ALL had completed treatment. Four factors 
showed the strongest relationship with cognitive difficulties. Researchers found a consistent 
pattern in the amount of time off therapy being correlated with greater negative effects. 
Cognitive late effects most typically would present between two to five years off therapy and 
then level off (Brown et al., 1992; Copeland et al., 1988; Jankovic et al., 1994). Research also 
found strong evidence that children diagnosed and treated under the age of 5 were more likely to 
have cognitive late effects than children diagnosed at older ages (Cousens, Waters, Said, & 
Stevens, 1988). Additional research demonstrated links between gender and cognitive late 
effects, with poorer outcomes for females (Robison et al., 1984; Waber, et al., 1990). Finally, a 
number of studies found that higher doses of intrathecal chemotherapy were linked to greater 
long-term cognitive deficits (Kingma, et al., 2002; Lansky, Cairns, & Zwarjies, 1984; Williams, 
Ochs, Davis, & Daniel, 1986). Many of these earlier studies had methodological issues that 
persist today when studying children who had been treated for ALL. 
An important limitation with studying this population of children is that many studies 
focusing on neuropsychological effects of treatment include low numbers of children with ALL. 
For example, of the 28 studies in Campbell et al.’s (2007) meta-analysis of long-term 
neuropsychological effects on survivors of childhood ALL, 14 studies had groups of ALL 
children with fewer than 20 participants.  Seven of the studies had groups of participants that 
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ranged from 10 to 15 post therapy children with ALL.  Studies with small sample sizes are 
common when conducting a single site study with children with ALL, which create data analysis 
and generalization issues. Another complicating factor is that children with the same type of 
cancer may be treated on different protocols and receive different amounts of the same 
chemotherapy agent, or very different chemotherapy agents.  This presents an analysis problem 
in studies with small sample sizes. Despite the preponderance of small n studies, Campbell’s 
meta-analysis served to confirm the cognitive and academic late effects of treatments that 
include cranial-spinal radiation, as well as methodological issues in designing such studies.  
The studies from the 1980s and 1990s continued to find relationships between cranial-
spinal radiation therapy and cognitive and academic decrements.  Given this evidence, the 
leading pediatric association recommended treating children with low or standard risk ALL using 
systemic and intrathecal chemotherapy, without cranial-spinal radiation therapy.  They believed 
these new protocols would eliminate the neurocognitive late effects experienced by children, 
without compromising mortality rates. Protocols that excluded the use of radiation and only 
included systemic chemotherapy (SC) and intrathecal chemotherapy (IT) were developed. These 
protocols demonstrated effectiveness at curing leukemia at rates similar to protocols that 
included cranial-spinal radiation.  A large scale study by Mitby et al. (2003) estimated that 
approximately 40% of survivors of childhood ALL would receive some special education 
services during their school years, though causation was unclear.  To what extent number of 
intrathecal chemotherapies and time off therapy impact neurocognitive late effects needed 
further exploration, with more adequate controls.  Regardless, this shift in treatment protocols 
then led to a number of studies that evaluated the effects of leukemia SC and IT chemotherapy 
protocols on toxicity of treatment and neurocognitive late effects, as well as the relationship of 
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time off therapy to the appearance of these weaknesses. Evidence from many of these 
studies found that large doses of IT chemotherapy adversely affects brain structures, particularly 
white matter, which is believed to lead to information processing challenges, which cause the 
weaknesses in achievement functioning.   
The current study was designed to assess the neurocognitive outcomes of non-radiation 
ALL treatment in relation to number of intrathecal injections and time off therapy, while using 
healthy siblings as controls for the cancer experience.  It was predicted that participants with 
ALL in the high IT and high TOT groups would show greater neurocognitive weaknesses than 
the low IT and low TOT groups, when compared to their healthy siblings. This study expanded 
on the achievement and neuropsychological variables measured in prior studies.  It also 
controlled for family factors by using siblings as controls.  The results were expected to have 
implications for treatment protocols and psycho-educational interventions that would allay 
predictable weaknesses related to ALL therapy. 
 Chapter 2 presents a more in-depth understanding of childhood ALL treatment and the 
effects of cranial-spinal radiation and/or, systemic and intrathecal chemotherapy, on the 
cognitive, academic achievement, and neuropsychological outcomes for children who had been 
treated for ALL.  
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Chapter 2: Literature Review 
Due to the negative cognitive, achievement, and neuropsychological outcomes of the 
treatment protocols that included cranial-spinal radiation treatment, treatment of childhood ALL 
shifted to systemic and intrathecal chemotherapy protocols that did not include any radiation. 
This review will explore the literature comparing the neurocognitive outcomes of protocols that 
included cranial-spinal radiation to those that did not. This review also will explore the systemic 
and intrathecal treatment literature that focuses on neurocognitive late effects for children with 
acute lymphocytic leukemia. 
Effects of Cranial-Spinal Radiation Treatment Compared to Systemic and Intrathecal 
Chemotherapy Treatment 
Smibert, Anderson, Godber, and Ekert (1996) conducted one of the first studies to 
compare cranial-spinal radiation to systemic and intrathecal chemotherapy treatment approaches.  
This study was interested in the long-term intellectual and academic outcomes for post therapy 
children with ALL. A large sample (n = 100) of childhood leukemia participants treated with 
both irradiation and chemotherapy was compared to a healthy control group (n = 100) and a 
comparison group of children with mixed cancers (n = 50) who received chemotherapy, but not 
radiation, as part of their therapy. The study found that children who received cranial-spinal 
radiation performed more poorly on measures of intelligence and academic achievement than 
either the healthy control group or the mixed cancer comparison group that received SC or SC + 
IT but no radiation. Additionally, a younger age at treatment (< 5 years) and a higher amount of 
radiation were predictive of poorer intellectual and academic performance. The participants who 
received SC or SC +IT chemotherapy without radiation performed similarly to the healthy 
control group. One limitation of the Smibert et al. study was that the chemotherapy only group (n 
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= 50) was a mix of different childhood cancers, some who received intrathecal chemotherapy (n 
= 24) and others only systemic chemotherapy (n = 26). Similar findings were noted by several 
other studies (Barrera, Shaw, Speechley, Maunsell, & Pogany, 2005; Langer et al., 2002; 
Raymond-Speden, Tripp, & Lawrence, 2000; Spiegler et al., 2006). While all of these studies 
used comparison groups, none utilized any type of matched controls; thus demographic factors 
such as socio-economic status (SES), parent education level, gender, and age were left 
unaccounted for. Regardless of the methodological limitations, significant negative effects of 
cranial-spinal radiation on cognition and academic achievement when compared with SC and IT 
treatment was undeniable. 
Hill et al. (1998) reported similar findings when comparing long-term effects on children 
with ALL treated with systemic and intrathecal chemotherapy (specifically, methotrexate), with 
and without cranial-spinal radiation (n = 110). This study also focused on psychosocial long-term 
effects, as participants were between 14 years - 4 months to 14 years - 9 months since the time of 
diagnosis. In addition to poorer academic outcomes, this study found that children with ALL 
who received systemic and intrathecal chemotherapy and radiation treatment reported having a 
poorer self-image and greater psychological stress than children with ALL who received 
systemic and intrathecal chemotherapy treatment without radiation. This study used subjective, 
self report psychosocial measures to examine psychosocial outcomes for children with ALL. 
In addition to intellectual and academic difficulties, researchers have found gender 
specific effects of ALL treatment as well. Précourt et al. (2002) were interested in the long-term 
effects of verbal learning ability for female children with ALL. They compared girls who 
received systemic chemotherapies, intrathecal chemotherapies, and cranial-spinal radiation (n = 
9) to girls who received only systemic chemotherapies and intrathecal chemotherapies (n = 10).  
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The study used a healthy control group of girls (n = 10). Only the group receiving systemic and 
intrathecal chemotherapies plus cranial-spinal radiation performed more poorly than the control 
group on verbal learning and passage comprehension.  
Around this same time, researchers became particularly concerned with the late effects of 
one chemotherapy agent, IT methotrexate. This chemotherapy agent was found to cause greater 
cognitive late effects in female children with ALL than other chemotherapies, when injected into 
the central nervous system.  However, IT methotrexate also had been found more effective in 
treating the disease (Mulhern, Fairclough, & Ochs, 1991; Williams, Ochs, Davis, & Daniel, 
1986). Methotrexate, when used as a systemic chemotherapy agent, had not been found to cause 
neurocognitive late effects in children being treated for cancers other than leukemia (Anderson, 
Smibert, Ekert, & Godber, 1994; Lansky et al., 1984). 
Looking at neuropsychological outcomes of treatment, Campbell et al. (2007) conducted 
a meta-analysis of childhood ALL studies that used systemic and intrathecal chemotherapy, with 
or without cranial-spinal radiation. Twenty-eight studies from 1980–2004 were used.  The 
participants were in first remission and nationally normed psychometric measures were normed 
nationally. The meta-analysis found evidence that cranial-spinal radiation, in combination with 
systemic and intrathecal chemotherapy, has a detrimental effect on overall intellectual 
functioning when compared with non-ALL controls. Age at time of diagnosis and time off 
therapy provided mixed results in this meta-analysis.  
A national Canadian study (Barrera, Shaw, Speechley, Maunsell, & Pogany, 2005) 
reviewed the educational and social outcomes for survivors of various childhood cancers (n = 
800) and compared these outcomes with healthy age and gender-matched controls (n = 923). The 
findings indicate that survivors who received central nervous system treatments—such as cranial 
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radiation alone, or cranial radiation together with systemic chemotherapy and intrathecal 
chemotherapy, or systemic chemotherapy and intrathecal chemotherapy—were more likely to 
struggle in school, be placed in special education, and be at greater risk for academic and social 
difficulties at school than survivors of childhood cancers that required no central nervous system 
treatment. Of the 800 childhood cancer survivors, 293 were leukemia survivors. The leukemia 
survivors were considerably more likely than the control group to be enrolled in special 
education, be identified with a specific learning disability, repeat a grade, and have other school 
problems. This study found that one of the academic areas in which survivors struggled was 
English, but did not distinguish if reading and writing were of particular concern for this 
population. Survivors with central nervous system tumors (such as brain tumors) and who 
received cranial radiation demonstrated the greatest difference from the control population, 
followed by participants who received central nervous system treatment for leukemia. Leukemia 
patients treated with cranial radiation were more likely than those treated with systemic and 
intrathecal chemotherapy to demonstrate the above school issues.  
Some investigators focused more particularly on how survivors’ attention and 
information processing impact their academic and social experiences. Spiegler et al. (2006) 
compared neurocognitive outcomes of ALL treatment with or without cranial-spinal radiation. 
The study also included two groups that received systemic and intrathecal chemotherapy, but no 
radiation: the high dose methotrexate group (n = 32) (HD-MTX), and the very high dose 
methotrexate group (n = 22) (VHD-MTX). An additional group received cranial-spinal radiation 
but no intrathecal chemotherapy (n = 25) (CRT). As with previous research, the CRT group 
performed significantly worse than the HD-MTX and the VHD-MTX groups on intelligence, 
memory, and academic measures. On an attention measure, children with ALL treated with HD-
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MTX and VHD-MTX protocols performed close to the population norms, with the exception of 
greater impulsivity on the Delay task of the Gordon Diagnostic System. 
Over time, treatment protocols for children with ALL have excluded cranial-spinal 
radiation because of its strong association with cognitive late effects.  Investigations 
subsequently explored the more subtle difficulties of post therapy children with ALL who 
received intrathecal and systemic chemotherapy treatments without cranial-spinal radiation. 
Effects of Systemic and Intrathecal Chemotherapy Treatment 
The treatment effects of childhood ALL chemotherapy-only protocols is an important 
area of study. All childhood ALL treatment protocols require some IT chemotherapy to achieve 
curative effects. The first treatments of this kind began in the mid-1980s.  By eliminating cranial 
radiation (CRT) from the treatment regimen, it was hoped that children with ALL would not 
experience any neurocognitive late effects. However, research on combined systemic and 
intrathecal treatments made clear that children with ALL were still at risk for neurocognitive and 
achievement delays, even when treated without cranial-spinal irradiation (Armstrong et al., 1999; 
Butler & Copeland, 2002; Cousens et al., 1998; Essig et al., 2014; Hill et al., 1998). The focus of 
late effects research sought to understand which treatment variables most predicted specific 
neurocognitive and educational risk areas for survivors treated with systemic and intrathecal 
chemotherapy.  
Based on findings from the 1990s, ALL researchers increasingly controlled for age, 
gender, cumulative dosage, and time off therapy to better understand the neurocognitive and 
achievement decrements revealed by the research. Research began to focus more specifically on 
processing issues such as attention, memory, visual-motor performance, and processing speed. 
Among the sizable number of studies conducted in the 1990s and early 2000s, the neurocognitive 
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late effects findings often were mixed. The findings of studies that targeted specific aspects of 
information processing are reviewed below. 
Intelligence and achievement.  
A national study by von der Weid, Mosimann, and Hirt (2003) compared 132 children 
with ALL who had received systemic and intrathecal chemotherapy treatments in Switzerland to 
100 childhood cancer survivors who received no central nervous system treatment. The findings 
demonstrated both age (less than six at age of diagnosis) and gender (female) as risk factors for 
decreased intellectual functioning in children with ALL after treatment was concluded. A meta-
analysis by Peterson et al. (2008) found relative delays in intelligence, mathematics, reading, 
attention, perceptual reasoning, processing speed, verbal memory, and executive functioning 
among post therapy children with ALL. Campbell et al. (2007) and Lyer, Balsamo, Bracken, and 
Kadan-Kottick (2016) also found weaknesses in intelligence, academic achievement, and several 
neuropsychological domains.  
Espy et al. (2001) was one of the first studies to use growth curve analysis to explore 
treatment-related neuropsychological outcomes in children treated with SC + IT protocols. The 
investigators administered a psycho-educational assessment battery that included traditional tests 
of intelligence and achievement and a comprehensive memory and processing battery. 
Participants were tested at eight months, two, three, and four years post-diagnosis.  Compared to 
test norms, the investigators found declines in arithmetic skills, visual-motor integration, and 
verbal fluency for children with ALL at four years post therapy. There was no relationship 
between the rate of decline and the specific SC + IT protocol.  
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Attention. 
Mennes et al. (2005) focused on attention and the processing speed of children with ALL. 
Twenty-three post therapy children with ALL who were treated on two European protocols that 
included systemic and intrathecal chemotherapies were compared to 23 age and gender matched 
controls. No difference was found between the two groups on sustained attention, inhibition, 
organization tasks, and simple baseline speed (the study used a simple mouse click response time 
activity). However, on more complex executive function tasks, children with ALL performed 
significantly worse than their healthy peers on focused attention tasks, memory recall, and 
memory search. Carey et al. (2008) and Butler et al. (2016) also found that post therapy children 
with ALL who had received systemic and intrathecal chemotherapies demonstrated lower 
performance on attention tasks, mental flexibility, visual-construction skills, and math 
achievement than the healthy control group.  
Fine-motor. 
In a sibling control study, Jansen et al. (2008) focused on the neuropsychological 
function over time of children with ALL who had received systemic and intrathecal 
chemotherapies. Forty-nine children with ALL were compared to 29 healthy siblings on fine-
motor and perceptual functioning, memory and learning, sustained attention, speed, and 
executive functioning, at two time points: 3 to 6 months off therapy and 2.5 years off therapy. 
The study had two significant findings: 1) children with ALL demonstrated significantly weaker 
fine-motor skills over time than the sibling control group, and 2) children with ALL who 
expressed greater pain or fatigue during treatment demonstrated poorer sustained attention years 
after completion of treatment, in comparison to the sibling control group. 
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Memory. 
Kingma et al. (2002) conducted a seven-year longitudinal study that focused on memory, 
intelligence, attention, processing speed, and motor skills of 20 children with ALL who had 
received systemic and intrathecal chemotherapy. Compared to a healthy control group, findings 
demonstrated relative delays in memory and fine-motor ability for post therapy children with 
ALL. In a similarly designed study, Kaemingk, Carey, Moore, Herzer, and Hutter (2004) 
compared  children with ALL who had received systemic and intrathecal chemotherapy 
treatment with 15 healthy controls. The control group was comprised of matched age and gender 
participants utilizing siblings and friends. While the children with ALL performed mostly in the 
normal range, relative difficulties in memory, psychomotor speed, math calculation, math 
reasoning, attention, and visual-motor ability were noted. 
In a small single site study, Hill et al. (1998) controlled for age, gender, SES and 
handedness to strengthen their study. This was one of the first studies to use a normed memory 
measure (the Wide Range Assessment of Memory and Learning). The research focused on the 
impact of systemic and intrathecal treatment on visual and verbal memory. Ten post therapy 
children with ALL were compared with ten healthy controls. The study showed relative delays in 
visual and verbal short-term memory, planning, and inattention issues for the children with ALL, 
in addition to 10-20 point deficits in intellectual scores.   
In Ashford et al.’s (2010) childhood ALL study of working memory, post therapy 
children with ALL were placed into either low- or high-risk groups based on cumulative 
treatment dosage and number of intrathecal treatments: 13 to 18 treatments in the low risk group 
and 16 to 25 treatments in the high-risk group. This study found that the high-risk treatment 
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group underperformed when compared to normative data on tests of Digit Span Forward (DSF), 
Digit Span Backwards (DSB), and Total Digit Span (TDS). The low-risk treatment group had 
difficulty with the Digit Span Backwards only. 
Processing speed. 
Mahone, Prahme, Ruble, Mostofsky, and Schwartz (2007) compared the motor 
processing speed of children with ALL (n = 22), who had received systemic and intrathecal 
chemotherapy treatment, with age and gender matched healthy controls. Participants completed 
computer-based motor timed tasks as part of a larger neuropsychological battery. The ALL group 
performed more poorly than the control group on motor processing speed and in ability to 
estimate durations of time. Other studies also have noted relative delays with visual-motor speed 
(Buizer et al., 2005; Cheung & Krull, 2016; Kaemingk et al., 2004; Kingma et al., 2002). 
 Using a sibling comparison group, Reeves et al. (2007) assessed whether post therapy 
children with ALL have delays in processing speed and if this relates to behavioral symptoms. 
Eighty post therapy children with ALL and 19 sibling controls were studied using processing 
speed and achievement measures, and an abbreviated IQ test (three WISC-IV subtests: 
Information, Similarities, and Block Design). Behavior was measured using the Child Behavior 
Checklist (CBCL). The study found that children who had been treated for ALL had more 
processing speed delays than their sibling controls. The siblings scored higher than the ALL 
group on all measures of intelligence and academics, with the exception of numerical operations. 
In summary, the findings from research on cognitive, achievement, and information 
processing functioning of children with ALL who had received SC and IT treatment suggests 
they are at greater risk for mild difficulties in intellectual functioning, academic achievement, 
memory, fine-motor skills, processing speed, and attention even without receiving cranial 
  15 
 
 
radiation therapy.  Today, the combined SC and IT therapy remains the most common treatment 
approach for childhood ALL (Anderson et al., 2009; Brown et al., 1998; Copeland et al., 1996; 
Espy et al., 2002; Lansky et al., 1984). Although lifesaving, these treatments come with 
neurocognitive risks. Therefore, continued study of neurocognitive outcomes for children with 
ALL is necessary.  
The findings from these studies raise questions about whether there are ways that the 
medical community can modify protocols and intervene preventatively if ALL treatment late 
effects are likely.  If not, are there ways that educators and therapists can monitor, prevent, and 
remediate weaknesses more effectively? Are there therapy protocols that have less negative 
outcomes? To better understand the relationship between treatment and cognitive, academic and 
neuropsychological functioning, researchers have studied the effects of time off therapy, and 
they are increasingly utilizing a combination of brain imaging and neuropsychological testing to 
research these complicated effects.   
Time off Therapy Effects of Systemic and Intrathecal Chemotherapy  
Time off therapy has continued to be a focus of study, as neurocognitive and achievement 
delays may not be visible immediately after treatment, but do become evident over time.  
Copeland, Moore III, Francis, Geffee and Culbert (1996), for example, compared the cognitive 
and academic effects experienced by 51 children with ALL, who had received systemic and 
intrathecal chemotherapy treatment, to 48 children with other cancers who had received only 
systemic chemotherapy. Intelligence, memory, language, achievement, fine-motor, perceptual-
motor, and tactile-spatial skills were assessed. Both groups showed declines on achievement 
scores, with time off therapy (TOT) becoming an important variable by three years post 
treatment. For the children with ALL, being treated at a young age (< 5 years) and the more time 
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off therapy (5 to 11 years), the greater the decline in perceptual-motor ability. On the 
performance intelligence quotient, children with ALL who had received systemic and intrathecal 
chemotherapy treatments scored approximately 10 points lower than their childhood cancer 
counterparts who received no central nervous system treatment. During the baseline year, which 
began at the time of diagnosis, the IQ scores of both groups had been equivalent.  
Brown et al.’s (1996) study compared children with ALL who had been treated with 
systemic and intrathecal chemotherapy (n = 38) to children with other childhood cancer 
diagnoses who received only systemic chemotherapy treatment (n = 25). For the children with 
ALL, a steady decline was evident on the reading, writing, and arithmetic sections of the Wide 
Range Achievement Test over the four-year period from diagnosis.  There were no cognitive or 
achievement deficits for the mixed-cancer comparison group. The declines for the post therapy 
children with ALL were attributed to the intrathecal chemotherapy treatment. 
In another study, Brown et al. (1998) examined the cognitive and academic late effects 
among 47 children and adolescents with ALL who had been treated with the same systemic and 
IT chemotherapy protocol. All of the participants had been off treatment for two to seven years 
at the time of assessment. The study found a negative gender effect on nonverbal tasks for girls 
who were treated for ALL, when compared to the test’s normative data and to boys treated with 
the same protocol. The females with ALL scored close to one standard deviation below the mean 
on performance tasks, whereas the males with ALL scored within low average to average ranges.  
A study by Mulhern, Fairclough, and Ochs (1991) found that children with ALL who had 
received SC and IT therapy had average intelligence and achievement scores at one year off 
therapy. At four years off therapy intelligence scores held stable, but achievement scores, though 
still in the average range, had declined. In a similar study, Ochs et al. (1991) found that at a mean 
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time of six years off therapy, children with ALL showed decreases in Full Scale IQ and Verbal 
IQ scores, as well as math achievement. Late effects for achievement began to show sometime 
between two and four years, with IQ late effects presenting between four and six years post-
therapy. 
Espy et al. (2001) too found that children with ALL demonstrated declines in verbal 
fluency, math, and visual-motor processing skills if they were more than two years off therapy. 
In their study, Kingma, Van Dommelen, and Mooyaart (2001) studied late effects at two time 
points: 3-6 months post treatment (T1) and approximately 2.5 years post treatment (T2). No 
intellectual changes were found from T1 to T2, but auditory memory and fine-motor difficulties 
did become apparent at T2. In a study published a year later, Kingma et al. (2002) report that at 5 
years off therapy the children with ALL (n = 20) had lower Verbal IQ and attention when 
compared to the healthy control group. 
Finally, Jansen et al. (2006), Lyer et al. (2016), and Nathan et al. (2006) found small 
decreases over time in intellectual function for children with ALL. These studies were 
longitudinal in nature and focused on time off therapy of under two years post treatment and 
again at 5 + years post treatment. Collectively, these studies suggest there is a likelihood of late 
effects becoming apparent in intelligence, achievement, perceptual-motor skills, auditory 
memory, and attention skills at approximately 5 or more years post therapy. Sometimes effects 
present as early as two years off treatment on verbal fluency, spelling, reading, math, visual-
motor, auditory memory, and fine-motor skills. 
These studies were critical to the understanding that, despite the exclusion of cranial-
spinal radiation as part of curative therapy for childhood ALL, systemic and intrathecal 
chemotherapy combined can still cause skill decrements, especially as time off therapy increases. 
  18 
 
 
These studies provide some depth of knowledge regarding neurocognitive and achievement late 
effects among children with ALL who had been treated with SC and IT chemotherapy. More 
recently, research has approached the issue of late effects of childhood ALL by utilizing more 
extensive neuropsychological batteries together with brain imaging techniques.    
Brain Physiology Research on Post Therapy Children with ALL  
As the neurocognitive effects of ALL systemic and intrathecal chemotherapy treatment 
have become evident, understanding the biological mechanisms that underpin these changes has 
become a priority. The brain is the primary organ of interest for children with ALL in relation to 
late effects. What is unclear is which biological system(s) within the brain are responsible for 
cognitive difficulties faced by ALL survivors. Among the more robust theories is that ALL 
treatments may affect brain matter in ways that make cognitive development more difficult. The 
brain consists of what is commonly referred to as white and gray matter. White matter is 
important because its neuron networks support messages being passed from one section of the 
brain (gray matter) to another. A prevailing theory is that damage to the white matter due to 
radiation or chemotherapy may disrupt this network (Reddick et al., 2003).  
To best research changes in brain structures, studies primarily have utilized MRIs, which 
create static images of the participant’s white and gray matter. For example, Montour-Proulx et 
al. (2005) conducted a study that included traditional MRI imaging technology for children with 
ALL who had been treated with SC and IT. This study used Growth Curve Analysis to study 
how participants (n = 24) performed on measures of intelligence and memory. The advantage of 
using this regression technique is that the researchers could analyze both group and individual 
effects over time. This study took place over two time periods: Time 1 was while on treatment, 
and Time 2 was sometime between 9 months to 2.5 years off therapy. The results of this study 
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demonstrated a reduction in white matter over the two time points that correlated with a 
significant reduction in Performance IQ scores.  
Reddick et al. (2006) utilized imaging technology with neuropsychological testing and 
demonstrated that post therapy children with ALL between the ages of six and eighteen (n = 112) 
had neurocognitive delays and reduced white matter associated with those relative delays, when 
compared to healthy siblings (n = 33). The findings demonstrated statistically significant 
academic and attention delays for the children with ALL, who received cranial-spinal radiation 
plus systemic and intrathecal chemotherapy. Attention delays were more than one SD below the 
norm. Regarding the white matter, participants who received systemic and intrathecal 
chemotherapy without radiation had considerably more white matter than their peers treated with 
chemotherapy and cranial-spinal radiation, but both groups had less white matter than the healthy 
sibling controls. Smaller white matter volumes were associated with relative delays in attention, 
IQ, and academics. More aggressive treatments produced more detrimental physiological and 
cognitive outcomes. 
Ashford et al. (2010) conducted the only brain imaging study that focused on the number 
of ITs, as they relate to neuropsychological outcomes. Their study examined the difference in 
white matter volumes between a high IT (16-25) and a low IT (13-18) group of post therapy 
children with ALL. IT groupings were based on a combination of number of ITs and total dosage 
of chemotherapy. The findings indicated that the high IT group exhibited a greater risk for 
leukoencephalopathy (white matter disease), working memory weaknesses, and attentional 
difficulties.  
Other structural differences in the brains of children treated for ALL have been suggested 
by Lesnik, Ciesielski, Hart, Benzel, and Sanders (1998). Lesnik et al. conducted an imaging 
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study of 6-13 year old childhood participants with ALL (n = 10) who had received systemic and 
intrathecal chemotherapy. Results were compared to matched age and gender controls. Structural 
brain differences in children with ALL demonstrated reduction in both left and right prefrontal 
cortical areas, which corresponded with delays on tasks of visual-spatial attention, short-term 
memory, and visual-motor organization.  
Oxidized cerebral spinal fluid is also implicated in delays that follow SC + IT treatment 
for ALL.  Caron et al. (2009) measured oxidative stress (the body’s increase in oxidizing of 
blood and a decrease in levels of antioxidants) over the first two years of treatment by collecting 
spinal fluid during scheduled lumbar punctures, and then analyzing the oxidative levels in the 
cranial spinal fluid. Executive functioning was tested over a three-year period after the 
completion of therapy. The study found correlations between higher oxidative stress and lower 
executive functioning at the two year post-treatment point of the study. In addition, there was a 
significant correlation between younger age at diagnosis, higher oxidative stress levels, and 
lower executive functioning ability. How oxidative stress levels might impact the brain is 
unclear, but the findings overall indicate that children with ALL must cope with an array of 
physiological changes that are detrimental to their cognitive functioning.  
In contrast to an MRI of the brain, which is a static image, functional MRIs (fMRI) 
provide images of the brain in an active state. Using fMRI, in conjunction with an executive 
functioning cognitive rehabilitation curriculum, Kesler, Lacayo, and Jo (2011) conducted a study 
with 23 post therapy children with ALL. This study concluded that the cognitive rehabilitation 
curriculum improved executive function and memory skills, based on neuropsychological test 
changes (processing speed, sort test, verbal and picture memory) as well as brain activation as 
noted in the fMRI (increases in dorsal lateral prefrontal cortex activation).  
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Robinson et al. (2010) utilized fMRIs to examine working memory and executive 
functioning in children with ALL who had received systemic and intrathecal chemotherapy 
between the ages of 10 to 16 years old (n = 8). Controls included age and gender matched 
healthy peers (n = 7). The study found that children with ALL did more poorly on tasks of 
working memory accuracy and had greater brain activity when focusing on working memory 
tasks. The dorsolateral and ventrolateral prefrontal cortex showed substantial activation during 
these tasks. In addition, the dorsal and ventral anterior cingulate cortex (involved in problem 
solving, motivation, and assessing emotional information) demonstrated larger activation on 
error monitoring tasks. Both of these findings suggest that compensatory activation was needed 
in these brain regions to complete executive functioning tasks.  
In summary, many of the imaging studies of children who had been treated for ALL 
relate their changes in brain state and function to decrements in neuropsychological functioning. 
These decrements are associated with physiological effects from treatment. Taken together, the 
imaging and neurocognitive research has provided stakeholders with a more complete 
understanding of the cognitive challenges faced by post therapy children with ALL on a daily 
basis. Potential difficulties in academic performance (math and reading), intellectual functioning, 
processing difficulties (visual-motor, fine-motor, and processing speed), short-term and working 
memory, and difficulties with executive functioning skills (planning and organization, attention, 
and multistep problem solving) are possible effects of chemotherapy treatment. More research is 
necessary to better predict which children with ALL are likely to struggle and when. Exploring 
ways to minimize negative effects and predict those children at greatest risk, without 
compromising treatment efficacy, is an important task. These findings offer areas ripe for 
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research on how to support children’s ability to develop compensatory neural processes that 
might mitigate some of the negative physiological effects of treatment. 
Summary of Childhood ALL Neurocognitive and Achievement Research 
Lifesaving treatment for childhood acute lymphocytic leukemia has been ongoing since 
the 1970s. The success rates and reduction of long-term effects for children with ALL have 
increased dramatically over the past 50 years as treatment protocols shifted from including 
cranial-spinal radiation, intrathecal, and systemic chemotherapies, to less toxic intrathecal and 
systemic chemotherapy only protocols. Factors such as 1) a younger age at diagnosis and initial 
treatment (with females being more susceptible than males), 2) time off therapy with 
neurocognitive late effects presenting at approximately five or more years off therapy, but 
sometimes sooner, and 3) higher cumulative doses and numbers of intrathecal chemotherapy 
treatments often have been associated with negative neurocognitive effects.  However the 
majority of the findings from these studies demonstrate that children with ALL typically perform 
in the average range, albeit significantly lower then their comparison groups (Ashford et al., 
2010; Brown et al., 1996; Buizer et al., 2005; Cheang & Krull 2015; Espy et al., 2001; Essing et 
al., 2014; Jansen et al., 2008; Kaemingk et al., 2004; Kanellopoulos et al., 2016; Lyer et al., 
2016; Reddick et al., 2006;  Waber et al., 2007). Although recent research has become more 
specific regarding the effects of chemotherapy, more studies are needed to better understand 
these cognitive, educational, and neuropsychological outcomes in children treated for ALL.  
In pursuing this line of research, adequate control groups are essential.  Some studies 
have had no controls, some do match on several variables, and others use mixed control groups 
of friends, siblings or convenience samples of healthy peers. It is common to simply compare the 
performance of children with ALL to standardized test norms. Thus far, siblings have been used 
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sparingly as a healthy control group in childhood cancer research. A review of the literature 
reveals that only six empirical studies of SC + IT treatment effects since the 1980s have included 
siblings of children with ALL (Jansen et al., 2008; Kaemingk et al., 2004; Mitby et al., 2003; 
Reddick et al., 2006; Reeves et al., 2007; Rodgers, Marckus, Kearns, & Windebank, 2003). Of 
these six, three used a battery of neurocognitive tests, including intelligence, achievement, and 
executive functioning assessment (Jansen et al. 2008; Reddick et al., 2006; Reeves et al., 2007). 
All three of these studies were whole-group comparisons and used a smaller number of siblings 
than the number of children with ALL in the studies, primarily for the purpose of ensuring that 
basic demographic and intellectual functioning was controlled. The use of healthy sibling 
controls, one-to-one matches, has the advantage of controlling for SES, race/ethnicity, parent 
education, genetics, home climate, and the shared crisis experience. Ideally, this research would 
be best suited to a twin study, but finding sets of twins where one is diagnosed with leukemia 
and one is not is almost unheard of.  
Taken as a whole, studies of the neurocognitive and achievement effects of childhood 
ALL treatments leave little room for questioning the general phenomenon of long-term effects. 
Using a range of methodological approaches, these studies established that many children who 
undergo treatment for ALL face later learning challenges, even though they may score in the 
average range on many of the neuropsychological and achievement measures. 
Although childhood cancer treatment has made great strides in increasing life expectancy 
and reducing overall neurocognitive deficits due to treatment, intellectual, academic and 
neuropsychological relative delays remain. These delays are milder than treatments that include 
cranial radiation, but they nevertheless remain persistent, subtle, and varied. Because of the set of 
findings around the late-term neurocognitive effects for children with ALL, it is critical that we 
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continue to deepen our understanding of the consequences of various combinations of 
treatments. This understanding can lead to revising treatment protocols and a greater focus on 
early intervention for predictable cognitive, achievement, and neuropsychological weaknesses. 
 
Current Study 
The primary research question in the current study was how high vs. low numbers of 
intrathecal treatments, and high vs. low time off therapy relate to specific cognitive, 
achievement, and neuropsychological outcomes for children who had been treated for ALL, 
when compared with their siblings. This study examined the effects of ALL treatment by 
creating high and low IT groups based on the number of intrathecal chemotherapies (< 20 or > 
20).  High and low time off therapy groups also were created based on five or more, vs. below 
five, years off therapy. The IT and TOT group cut offs were based on research showing more 
neurocognitive late effects with 20 or more ITs, or at 5 or more years off treatment.  
The current study used a healthy sibling control group in order to better control for the 
family’s cancer experience, as well as for demographics, such as SES and parent educational 
level. These factors have seldom been considered when studying late effects among children 
with ALL. Previous research comparing post therapy children with ALL to their healthy sibling 
counterparts has found differences in intellectual, achievement, processing speed, memory, fine-
motor, visual-motor and attention domains (Janson et al., 2008; Kaemingk et al., 2004; Reddick 
et al., 2006; Reeves et al., 2007; Rodgers et al., 1999). The current study explored these domains 
but also added some measures seldom used in ALL studies: Executive Functioning Scale, 
Reading Comprehension, Phonemic Awareness, Math Reasoning, and Writing Sample. 
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 Knowing that neurocognitive late effects can appear as early as two years off therapy 
and become even more evident at five or more years off therapy, this study examined how 
weaknesses would manifest in children with ALL with high vs. low time off therapy and with 
high vs. low numbers of intrathecal treatments. It was predicted that children with ALL who 
were classified as high IT or high TOT would show greater weaknesses on the study’s measures 
than those in the low IT or low TOT groups, when compared with their healthy siblings.  
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Chapter 3: Method 
Rationale for the Method 
This study has taken advantage of the controls inherent in sibling controlled research 
designs. The primary advantage of this design is the ability to vary one aspect of the environment 
(childhood cancer treatment based on number of intrathecal chemotherapies or time off therapy) 
while keeping much of the environment similar (home life, school, SES, and partial genetic 
control) (Donovan and Susser, 2011). This study design allows for exploration of whether 
analyzing sibling difference scores is helpful to statistical analysis when sample size is small. To 
date, no studies of children with ALL have used sibling difference scores for the data analysis. 
This study divided participants into a high and low group based on number of intrathecal 
chemotherapy treatments, and a high and low group based on time off therapy, in order to 
explore late effects on intelligence, academic achievement, and neuropsychological functioning 
among children treated for ALL. In addition to using measures common in late effect research 
(intelligence, verbal memory, executive functioning, attention, processing speed), this study also 
added measures of prose writing, math reasoning, pseudoword reading, reading comprehension, 
and parent rating of executive functioning.  
Participants 
Post therapy children with ALL and their healthy siblings were recruited from 
Tomorrows Children’s Institute. Sixteen families agreed to have both the child with ALL and a 
healthy sibling participate. Thirteen of the sixteen families were from Northern New Jersey and 
from either middle-class (average household income of $60,000 – $90,000) or upper middle-
class towns (average household income of $91,000 or more). All but one family identified as 
white. In total, 32 participants between the ages of 8 - 14 participated in this study.  Children 
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with ALL ranged in age from 8 years – 5 months to 14 years - 9-months, with a mean age of 11 
years -6 months. Healthy siblings ranged in age from 8 years - 0-months to 14 years - 7-months 
with a mean age of 11 years – 3 months. The average age for the children with ALL in this study 
was 142 months, while the average age for the healthy siblings participating in this study was 
138 months. Healthy siblings with any documented attention, learning, or cognitive disability 
were not permitted to participate in this study. The children with ALL had been diagnosed, 
treated, and/or were currently followed by the Department of Pediatrics at the Joseph M. Sanzari 
Children’s Hospital at Hackensack University Medical Center. All of the participants with ALL 
received both intrathecal and systemic chemotherapy treatments that included methotrexate 
chemotherapy, using one of four different childhood cancer protocols. All four protocols used 
intrathecal methotrexate, but three included two additional intrathecal medications.  Four 
potentially toxic systemic drugs were common to all protocols.  One protocol added a 5th drug, 
another added a 6th drug, and one added a 7th and 8th drug. 
This study included children with ALL between the ages of eight- and fourteen-years-old 
who were treated with systemic (SC) and intrathecal (IT) chemotherapy (no radiation therapy), 
and who had been off treatment for at least two years with no relapse. This combination of SC 
and IT is the most commonly used therapy for childhood ALL and research has consistently 
demonstrated that IT chemotherapy is linked to intellectual, cognitive, and information 
processing delays (Anderson et al., 2009; Brown et al., 1998; Copeland et al., 1996; Lansky et 
al., 1984).  
This study used 20 and above as the high IT group requirement, and five or more years 
off therapy as the high time off therapy group requirement. Because of the small sample size and 
use of four different treatment protocols, the cumulative dosage approach to classifying high vs. 
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low IT was not possible. Therefore, this study took an approach used in two prior studies, 
estimating high and low dosage levels from the number of ITs. Pui et al. (2003) extrapolated 
from their meta-analysis that 20 ITs is a likely threshold for increased risk of long-term cognitive 
effects. In addition, Ashford et al., (2010) conducted a study which grouped participants based 
on biological factors on MRI scans, number of intrathecal treatments, and cumulative dosage of 
chemotherapies.  Participants in Ashford et al.’s high risk group (16-25 ITs and greater 
cumulative dosage) performed more poorly on working memory tasks than participants who 
received lower numbers of IT (13-18) and lower cumulative dosage. In the current study, using 
the 20 IT cut off resulted in seven children with ALL being in the high IT group and nine being 
in the low IT group, with a sample mean for ITs of 18.81 (SD = 2.56). This study compared post 
therapy children with ALL with 20 or above ITs to those with 19 and fewer ITs. The field of 
childhood ALL research has been moving toward decreasing the amount of toxicity children 
receive, by decreasing both total number of ITs and cumulative dosage of chemotherapies. This 
is reflected in the study’s sample, where younger children with ALL were more prevalent in the 
low IT groups. This study excluded children with ALL who had received cranial-spinal radiation 
as part of their ALL treatment. Children with ALL also were excluded if they had any relapse or 
any secondary cancer. Finally, no children who had been off treatment for ALL for less than 24 
months were permitted to participate, as prior studies found that it is around age two that some 
late effects of treatment begin to appear.   
Based on literature showing that five years off therapy reveals more marked late effects 
on neurocognition than fewer years off therapy (Espy et al., 2001; Kingma et al., 2002; Nathan et 
al., 2007), five years or more off therapy was set as the high TOT group requirement.  Children 
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off therapy for less than five years were categorized in the low TOT group.  This resulted in nine 
children in the high TOT group and seven in the low TOT group.  
Healthy siblings of the children with ALL who were between the ages of eight and 
fourteen and who had no history of cancer were included in the study. The healthy sibling 
control group allowed the researchers to control for potential co-varying factors such as socio-
economic status (SES), parent education, race/ethnicity, the effects of the family crisis, and 
genetic propensity toward certain temperamental traits and abilities that impact cognitive and 
educational performance. Table 1 provides a list of sibling pair demographic data (see Appendix 
A for tables).  
Recruitment 
According to hospital records, 64 childhood cancer survivors met the criteria for this 
study. A chart review of these 64 survivors was conducted and 24 families were identified that 
had one or more siblings who also met the age and health criteria for this study. Potential 
participants were contacted via first class mail and invited to participate in the study. 
Approximately one week after receiving the letter, each family that had not already contacted the 
researcher received a phone call from the researcher inquiring about their interest. Of the 24 
families, 16 agreed to participate (participation rate of 67%). Four families did not respond to the 
letter or to the follow-up call, and four more families refused participation. Of the 16 families 
that agreed to participate, 14 families had a childhood cancer survivor who was male and two 
who were female, thus gender could not be analyzed as a factor in this study. Families that 
indicated interest were given opportunities to ask questions about the research during the phone 
call. Upon verbal agreement to participate, an appointment for the testing sessions was 
scheduled. Prior to the beginning of the testing session, the researcher gave the child (ages 9 to 
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14) an assent form and the parent/guardian the study consent form to read and review. The 
researchers verbally reviewed the assent form with 8-year-old participants as per hospital policy.  
Measures  
Intelligence. 
Intelligence Composite-Wechsler Intelligence Scale for Children–Fourth Edition. 
The Wechsler Intelligence Scale for Children – Fourth Edition (WISC-IV; Wechsler, 
2003) was used in this study as a benchmark of intellectual performance. For analysis, the 
current study drew from procedures used by Kadan-Lottick et al. (2009), who used the Full Scale 
Intelligence score. By using the Full Scale score on the WISC-IV, the intelligence quotient is 
comprised of subtests that measure verbal comprehension, perceptual-reasoning, processing 
speed, and working memory.  
The WISC-IV is a clinical instrument for measuring the intellectual capacity of children. 
The test comprises ten core subtests: Vocabulary, Similarities, Comprehension, Block Design, 
Picture Concepts, Matrix Reasoning, Digit Span, Letter-Number Sequencing, Coding, and 
Symbol Search. These subtests generate a Full Scale score (FSIQ), as well as four composite 
indices: Verbal Comprehension (VCI), Perceptual Reasoning (PRI), Processing Speed (PSI), and 
Working Memory (WMI). This instrument takes approximately one and a half hours for the child 
to complete. Inter-rater-reliability coefficients (how much agreement there is in the test scoring 
by different testers) for the Verbal Scale are .92 to .96 (average .95); Performance Scale are .89 
to .94 (average .91); and Full-Scale are .94 to .97 (average .96). Criterion validity compares the 
WISC-IV to previous versions of the WISC battery as well as other standardized cognitive 
measures, such as the Stanford-Binet and the Kaufman Assessment Battery for Children. The 
norm sample included 2,200 cases from across the nation, including 200 children in each of the 
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11 age groups (ranging from 6 to 16 years). Norming data also included representative 
percentages by socio-economic status, gender, and urban, suburban, and rural locations. 
Verbal memory. 
California Verbal Learning Test for Children. 
The California Verbal Learning Test for Children (CVLT-C; Delis, Kramer, Kaplan, & 
Ober, 1994) was used as the primary measure of verbal memory performance. To create a 
memory composite score, this study drew from procedures in Anderson et al. (2009) and 
Reddick et al. (2003) when using the CVLT-C. In both of these childhood cancer studies, the 
researchers used the List A Total Trials 1-5 score as the general measure of overall verbal 
memory performance. The CVLT-C assesses short-term and long-term memory in children ages 
five to sixteen. A list of 15 words that can be organized into three categories (e.g., fruits, 
clothing, and toys) is dictated to the child over five consecutive trials. The list of words is always 
read in the same order. The child is asked to verbally recall the words immediately following 
each trial. This instrument takes approximately 20 minutes for the child to complete, plus an 
additional 20-minute delay to assess long-term free and cued recall. Internal consistency on the 
test ranges from .81 to .91 across ages. Between trial consistency ranges from .84 to .91, and the 
semantic categories reliability coefficient ranges from .64 to .80. Word consistency ranges from 
.67 to .86. The CVLT shows moderate construct and content validity with the Wechsler 
Intelligence Scale for Children - Revised Vocabulary subtest, with correlations ranging from .32 
to .40. The norming sample consisted of 920 typically functioning children between the ages of 
five and sixteen, and controlled for location within the United States, socio-economic status, 
gender, and urban, suburban, and rural locations.  
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Executive functioning. 
 The Rey-Osterrieth Complex Figure Test. 
The Rey-Osterrieth Complex Figure Test (RCFT) (Osterrieth, 1944) was used as a 
measure of visual spatial organization and planning. This study drew procedures from Campbell 
et al. (2009) and Waber et al. (2007) for selection of subtests to examine planning and 
organization skills. The rationale for this choice is rooted in Waber’s long history of use of the 
RCFT with children with ALL, dating to the mid-1980s. Waber and Bernstein (1995) created the 
developmental scoring system for the RCFT. The RCFT is a tool designed to measure a child’s 
visual perceptual ability and organization of complex material by copying a figure and one 
minute later drawing it from memory. The child is given five markers to use to complete the 
copying task. The examiner asks the child to change markers upon request in order to better 
assess the child’s organizational approach to the task. Based on Campbell et al. (2009) and 
Waber et al.’s (2007) precedent, the current study used the RCFT Copy score, which scores the 
quality of copying rather than the child’s organizational approach. Because of the complexity of 
the figure, most children fail to reproduce it correctly. Production failure provides insight into the 
preferred problem solving and organizational approach of the learner (Meyers & Myers, 1995). 
Inter-rater reliability was randomly performed on 52 protocols with a reliability coefficient of .95 
for the Copy-Organization score. Inter-rater reliability coefficient for the Style (copy) score was 
.88). Raters’ ability to identify critical features ranged from .91 to .96 (Meyers & Meyers, 1995). 
Test-retest reliability was not calculated due to clinical considerations that would make this 
invalid (i.e., once a child has the experience of drawing the figure s/he is no longer naive to 
drawing it). This test was normed on 450 children ages 6 to 14. The RCFT norming data used in 
the current study was drawn from Myers & Meyers (1995) and consisted of 505 typically 
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functioning children between the ages of 6-years-0-months and 17-years-11-months from the 
Midwestern United States. In this norming sample the authors controlled for gender and 
socioeconomic status. 
Behavior Rating Inventory of Executive Functioning - Parent Form. 
The Behavior Rating Inventory of Executive Function (BRIEF) (Gioia, Isquith, & Guy, 
2001) was used in the current study as a measure of perceived executive functioning. A 
composite score to measure perceived executive functioning was necessary in order to maximize 
statistical power level and still analyze this domain. In order to create a composite score from the 
parent rating measure, the current study used the procedures in Sullivan and Riccio (2006), in 
which significant inter-correlations supported creating a Global Executive Composite from the 
BRIEF Inhibit, Initiate, and Monitor subscales. It is important to note that the BRIEF is missing 
data from two sibling pairs whose parents chose not to complete these forms. Therefore, analysis 
was conducted with an n= 28 (14 sibling pair difference scores) instead of n = 32 (16 sibling 
pair difference scores).  
The BRIEF is a questionnaire for parents of school-aged children five-to-eighteen-years 
old. This measure is normed on 1,419 parent and 740 teacher reports balanced for socio-
economic status, gender, and urban, suburban, and rural locations. The BRIEF has eight scales 
that focus on different aspects of executive function (Inhibit, Shift, Emotional Control, Initiate, 
Working Memory, Plan/Organize, Organization of Materials, and Monitor). Parents are asked to 
respond to the 86 items on a 3-point Likert scale ranging from Never, Sometimes, to Always. This 
instrument takes approximately 20 minutes to complete. The BRIEF’s internal consistency 
coefficients range from .80 to .98 on the Parent Form, and test-retest correlations range from .76 
to .88. Construct validity was determined by comparing the BRIEF to more general measures of 
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behavior such as the ADHD Rating Scale-IV, the Child Behavior Checklist Parent and Teacher 
Form, the Behavior Assessment System for Children, and the Connors’ Rating Scale. Through 
correlations and factor analysis, the BRIEF was found to correlate strongly with measures of 
general behavioral functioning, and to correlate less strongly with measures of emotional 
functioning.  
Attention. 
Test of Variable Attention. 
The TOVA was used in the current study to measure both inattentiveness and 
impulsivity. The current study drew from procedures used in Aijaz et al. (2006). In their study of 
medically fragile children, Aijaz et al. used attention composite scores to measure various 
aspects of attentional performance. Similarly, this study used the TOVA omission and 
commission scores to create two separate composite scores, one for inattention (omission) and 
one for impulsivity (commission) to analyze attention. Composite scores were necessary to 
maximize statistical power level for analysis of these domains. The composite scores were 
created by combining the four quartile error scores separately for omission and commission 
errors.  
The TOVA is a measure of sustained attention and examines the participant’s errors of 
omission (inattentiveness), commission (impulsivity), response speed, and variability of response 
rate. The child completes the task on the computer and is told to click a finger-button switch 
when a black box appears on top of the screen, and to not respond when the black box appears on 
the bottom. This instrument takes approximately 25 minutes for the child to complete. The test 
developers computed Pearson R correlations for all variables. Condition 1 (Quarters 1 and 2, 
stimulus infrequent) reported correlations across quarters ranging from .69 to .92. Condition 2 
  35 
 
 
(Quarters 3 and 4, stimulus frequent) reported correlations ranging from .70 to .92. Cronbach 
alpha, split-half, and Kuder-Richardson reliability coefficients, traditionally reported as a 
measure of test consistency, are not appropriate for timed tasks such as the TOVA (Anastasi, 
1988). Norming data consisted of 1,590 children and adults ranging from ages 4 to 80 from 
across the United States. The majority of those tested were from either rural or suburban 
Midwestern communities. The norming data controls for gender, but does not control for 
socioeconomic status. 
Processing speed. 
Test of Variable Attention. 
The Test of Variable Attention (TOVA; Greenberg, Kindschi, & Corman, 2000) was 
used in the current study as a measure of processing speed. Response time is the amount of time 
it took the subject to press the mouse button when the target was presented. The current study 
created a composite Response Time score drawing from Aijaz et al. (2006), who combined the 
four response time quartiles (Q1, Q2, Q3, and Q4) to create a composite score.  
 Academic achievement. 
Wechsler Individual Achievement Test Second Edition. 
The Wechsler Individual Achievement Test - Second Edition (WIAT-II; Wechsler, 2003) 
was used in the current study to measure academic performance in reading and math. Reading 
and math deficits for post therapy children with ALL are well documented (Armstrong et al., 
1999; Brown et al., 1998; Reddick et al., 2006). The current study created a composite score for 
reading (Reading Comprehension and Pseudoword subtests), based on the inter-correlation for 
these subtests reported by Wechsler (.48 - .65) on the Reading Comprehension and Pseudoword 
subtests. The WIAT–II Reading Comprehension requires students to read several passages 
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within a grade-appropriate item set and answer questions. Questions about the passages involve 
detecting the main idea and supporting details, making inferences, and defining vocabulary. The 
participants chose the best of four possible multiple-choice answers. The Pseudoword task 
required decoding phonemic nonsense words.  
The Math Reasoning task included counting, identifying shapes, and solving math word 
problems. Participants were presented a series of math problems, both verbally and by visual 
display, to assess their ability to reason mathematically. This test is not timed and participants 
could use scrap paper if requested. This test takes approximately 40 minutes to administer. 
Inter-rater reliability coefficients of WIAT-II subtests range from .71 to .99. Test-retest 
reliability for subtests range from .81 to .99. Construct validity with the Math Reasoning subtest 
and the WRAT3 Arithmetic Subtest is .77; WIAT-II Reading Comprehension subtest with 
WRAT3 Reading is .73. Norming data consisted of a national sample of 2,950 participants 
ranging in age from 4 to 19-years-11-months. Norming data also included variables such as 
socio-economic status, gender, and urban, suburban, and rural locations.  
Writing. 
Three-Minute Writing Sample. 
A three-minute writing sample was used to assess written expression abilities of the 
participants. There is no known research regarding written expression and skills of post therapy 
children with ALL. This task is not a nationally norm-referenced measure. The current study 
utilized the three-minute writing task procedures described by Malecki and Jewell (2003) as 
inter-correlations between total words written and the five other writing indices range from .56 to 
.99. Total words written is a standard measure in response to intervention writing assessment  
(Gansle, Noell, van der Heyden, Naquin, & Slider, 2002).  
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The Three-Minute Writing task was scored using an original data set analyzed across 
gender and grade level in the central United States (Malecki & Jewell, 2003). The participants in 
that study were 946 first- through eighth-grade students from three schools in rural and suburban 
northern Illinois. The sample consisted of 48% males and 51% females, but no other 
demographic data was reported. The participants consisted of 133 (14.1%) first-graders, 200 
(21.1%) second-graders, 168 (17.8%) third-graders, 192 (20.3%) fourth-graders, 127 (13.4%) 
fifth-graders, 57 (6.0%) sixth-graders, 44 (4.7%) seventh graders, and 25 (2.6%) eighth-graders. 
The original 3-minute writing task tested for Total Words Written, Words Spelled Correctly, 
Correct Spelling Sequences, and Percentage of Words Spelled Correctly. Reliability and validity 
data was not gathered. Studies find that three-minute writing samples correlate well with 
standardized writing achievement scores (Amato & Watkins, 2011; Fewster & Macmillan,2002).  
Procedures 
Participants were asked to complete approximately four hours of testing consisting of 
cognitive, academic, executive functioning, and information processing assessments across two 
2-hour sessions on the same day (e.g., 10:00 am to 12:00 pm, and 1:30 pm to 3:30 pm). 
Whenever possible, two participants were tested on the same day. This investigator was 
responsible for administering all of the executive functioning, memory, and achievement 
measures. A pediatric neuropsychologist administered all intelligence, attention, and processing 
speed measures.  
Testing was conducted at the Cure and Beyond Office (a cancer survivorship program) 
within Hackensack University Medical Center. While the child was completing the evaluation, 
the parent(s) were asked to complete two forms for further background information, along with 
the BRIEF, which measures their perceptions of their child’s executive functioning abilities. 
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Children with ALL and healthy siblings alternated between the two test administrators in the AM 
or PM to control for time of day. The measures administered to the participants were evenly split 
between AM and PM. One child in each family pair was administered the intelligence and 
achievement measures in the AM, while the other child was administered the executive 
functioning and information processing measures. The children switched measures for the PM 
assessment session. In four instances families were unable to commit to completing testing in 
one day and came back within two weeks to complete the testing. Within six weeks of 
completing testing, the investigator and neuropsychologist scored tests and provided a brief 
written report to the family describing their children’s functioning in each of the areas. Families 
also were given the opportunity to meet with the researcher to discuss findings further upon 
request. Upon completion of the testing, each participant received a $20.00 gift certificate to 
Barnes and Noble or Toys R Us. In addition, each family was provided $20.00 to cover travel 
expenses.  
Confidentiality 
The participants’ identities in this study remained confidential. Each participant was 
identified by a number code system created by the investigator and employed after testing was 
completed. This code was destroyed at the completion of this study and will not appear in any 
publications or presentations of this material. The investigator reviewed participants’ health and 
academic records. These records are maintained using the confidentiality rules set forth by 
Hackensack University Medical Center and the Health Information Personal Privacy Act 
(HIPPA) standards for medical, hospital, or psychiatric treatment records and are kept in a 
locked cabinet in a locked office.  
 
  39 
 
 
Research Design and Statistical Analysis 
The current study was designed to study the effects of high vs. low IT and TOT on the 
cognitive, academic, and neuropsychological functioning of post therapy children with ALL, 
using healthy siblings as the control. By using healthy siblings as the control, the data provide an 
estimate of developmental capabilities while also controlling for the family experience and 
demographics.  Gender analysis was not possible, as only two of the 16 children with ALL were 
female. 
The current study assessed the neurocognitive late effects for high vs. low number of 
intrathecal chemotherapy sessions. Typically, the more IT chemotherapy a patient receives, the 
higher the likelihood for cognitive late effects (Espy et al. 2001; Heukrodt et al., 1988). Based on 
findings in the research literature, participants were grouped either into the high IT group (20 or 
more ITs) or the low IT group (19 or fewer ITs). 
The current study also measured the effects of time off therapy (a variable often 
associated with cognitive late effects) by creating a categorical time off therapy factor: each 
participant was categorized as less than 5 years post treatment (TOT > 5 years), or 5 or more 
years post treatment (TOT < 5 years). All of the current study’s children with ALL were two or 
more years off therapy. The low TOT group’s ages ranged from 8 years – 5 months to 12 years – 
6 months.  The high TOT group’s ages ranged from 10 years – 4 months to 14 years – 9 months. 
The design is in line with previous childhood cancer research showing that some cognitive 
effects may present by two years off therapy, with even more late effects becoming apparent at 
five or more years off therapy (Brown et al., 1998; Copeland et al., 1996; Espy et al., 2001; 
Kingma et al., 2002; Nathan et al., 2007).  
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All of the measures used in this study, with the exception of the writing task, are 
nationally normed, age-based, standardized measures. The writing test is age-normed, but is 
based on norming data from one school district in the Midwest. Due to limited sample size, 
composite scores for measures were used when possible, rather than subtest analysis. When 
composite scores were unavailable, either a combined subtest score or individual subtest scores 
were used based on the practice in previous studies in the field of childhood ALL neurocognition 
and childhood illness. While information was requested from teachers on student achievement, 
there was a low response rate from teachers (4 out of the 16 children with ALL), and only 3 of 
the 16 healthy siblings. This information was not used as the majority of the data was 
incomplete. 
Initially, the analysis plan was to conduct eight 2x2 ANOVAs and one MANOVA on 
difference scores between children with ALL and healthy siblings. Inopportunely, for the 2x2 
ANOVAs, one of the cells (<19 ITs and >5 years TOT) had a n = 0, as children treated over five 
years ago typically received greater ITs (see Table 2: Scatter Plot). More recent protocols 
prescribe fewer ITs, in an effort to reduce the number of neurocognitive late effects, while 
keeping survivor levels at a high percentage. Therefore, the data were dealt with as two 
independent factors, one studying the effects of IT and one studying the effects of TOT. Thus, 
two analyses, with 10 one-tailed t-tests each, were conducted. For the t-tests, the factors were 
low and high number of intrathecal chemotherapies (IT), and low and high time off therapy 
(TOT). These t-tests were conducted on the sibling pair difference scores for each of the 
measures administered. Difference scores permitted analysis of data in a way that maximized 
power with a small sample size. 
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A Cohen’s d score was also calculated to analyze effect size of high vs. low IT and high 
vs. low TOT difference scores for each measure.  The Cohen’s d measures the ratio of difference 
between the means of two groups in relation to the size of their standard deviations (Sullivan & 
Feinn,, 2012). Effect size can be useful in studies with small sample sizes, where there is a 
greater likelihood of Type II error. According to Cohen (1992), typically 0.20 is considered a 
small effect size, 0.50 is considered a moderate effect size, and 0.80 is considered a large effect 
size. Unlike the Pearson r effect size, a Cohen’s d cannot account for a specific amount of 
variance; it can only be used in the context of identifying a small, moderate, or large effect size.   
Assessment of Violation of Assumptions 
T-tests were conducted on the following domains using the measures indicated: 
intelligence (WISC-IV full scale intelligence quotient), verbal memory (CVLT-C List A Trials 
1-5 score), executive functioning (RCFT Copy score), executive functioning – parent report 
(BRIEF Global Executive Composite score), processing speed (TOVA response time composite 
score), inattention (TOVA omission composite score), impulsivity (TOVA commission 
composite score), reading (WIAT-II  Reading Comprehension and Pseudoword composite 
score), math concepts (WIAT-II  Math Reasoning score), and writing (three minute writing 
sample – total words written score).  
This study used sibling pair difference scores to compare ALL children to a proximal 
representation (their siblings) of what their neurological function might have been without ALL 
treatment. The t-tests allow one to test the significance of the difference between children treated 
for ALL who have high or low numbers of intrathecal treatments and high or low time off 
therapy, and their siblings. The study protected against Type I error by using the Holmes-
Bonferroni a priori correction of the Alpha level to .005.  
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 Given the small sample size in this study, it is not surprising that testing of violation of 
assumptions finds the study underpowered.  A power analysis was conducted for an independent 
sample t-test to determine a sufficient sample size using an alpha of 0.005, a power of 0.8, a 
large effect size (d = 0.8), and one tail (Kock, 2015). Based on the aforementioned assumptions, 
the desired sample size was 39 pairs. 
Levene’s Tests for homogeneity of variance found homogeneity for eight of the ten IT 
analyses and eight of the ten TOT analyses. For IT, the homogeneity assumption was violated for 
inattention (p = .008) and impulsivity (p = .015).  When analyzing TOT, the homogeneity 
assumption was violated for inattention (p = .033) and Executive Functioning Parent Rating (p = 
051).  
A significant negative skew was found for: the high IT children with ALL on Reading     
(-2.06) and Processing Speed (-1.13); the low IT children with ALL on Processing Speed (-1.06) 
and Executive Functioning Copy (-1.03).  For the high IT siblings, a negative skew was found on 
Total Words Written (-1.16) and Executive Functioning Copy task (-1.21), and a positive skew 
on Reading (1.12). Platykurtic kurtosis was found for: high IT children with ALL on Executive 
Function Copy (-2.63) and the Executive Function Parent Rating (-2.23); the high IT siblings on 
inattention (-2.01) and impulsivity (-2.29).  Leptokurtic kurtosis was found on Reading for the 
high IT children with ALL (4.59) and the high IT siblings (2.03).  
A significant negative skew was found for: the high TOT children with ALL on Reading 
(-1.39); the high TOT siblings on IQ (-1.12), Reading (-1.02), Processing Speed (-1.52), and 
Verbal Memory (-1.40).  Reading had a significant negative skew for low TOT siblings (-1.35). 
Platykurtic kurtosis was found for the high TOT ALL children for Executive Function Copy      
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(-2.44), as well as for the high TOT siblings for Processing Speed (-2.22).  A leptokurtic kurtosis 
was found for the high TOT children with ALL for Verbal Memory (2.25). 
Given that this study was underpowered and that a number of the samples were not 
normally distributed, the findings must be interpreted with caution. In addition, interpretation of 
findings was complicated as all high IT children happened to also be high TOT, and all low IT 
children happened to also be low TOT; but two children crossed groups because they were low 
IT and High TOT. To assure the most conservative interpretation of findings, post hoc t-tests 
deleted the two “mixed” sibling pairs. The resulting comparison of only high IT and high TOT 
(n=7) vs. low IT and low TOT (n=7) sibling pairs, prevented the two mixed sibling pairs from 
exerting a disproportionate effect on this study’s findings. 
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Chapter 4: Results 
Descriptive Statistics 
This study used paired sibling difference scores on intelligence, achievement, and 
neuropsychological measures to assess the effects of high and low number of intrathecal 
chemotherapy treatments and high and low number of years off therapy on performance of 
children who had been treated for ALL. Group descriptive statistics indicate that mean scores for 
both the children with ALL and siblings are in the average ranges for the domains studied, with 
the exception of below average inattention among siblings (see Table 3). Descriptive statistics 
for the IT and TOT ALL groups are presented in Table 4. Descriptive statistics for the sibling IT 
and TOT groups are presented in Table 5. Scores on the measures with significant t-test findings, 
and large or moderate effect sizes, are found in Table 6 for children with ALL and Table 7 for 
healthy siblings.  
Sibling pair difference score groupings consisted of a high intrathecal (IT) group of >20 
IT (n = 7), a low intrathecal group of <19 IT (n = 9), high time off therapy (TOT) group of >5 
years (n = 9) and a low time off therapy group of <5 years (n = 7). The sibling pair difference 
score analyses for high and low number of intrathecal chemotherapy groups (IT) are presented in 
Table 8. The sibling pair difference score analyses for high and low time off therapy groups 
(TOT) are presented in Table 9. Negative difference scores indicate that the children with ALL 
performed more poorly than their healthy siblings. Positive difference scores indicate that the 
children performed better than their healthy siblings.  
Intelligence  
Participants scored within the average to high average range on the Wechsler Intelligence 
Scale for Children – Fourth Edition Full Scale IQ, with ten of the 16 children with ALL 
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performing more poorly than their healthy sibling. The subscale group means and standard 
deviations for children with ALL and their healthy siblings are presented in Table 10. The Full 
Scale WISC-IV scores of individuals with ALL ranged from 87 to 116 (M = 103.25, SD = 8.73) 
(see Table 11). Full Scale WISC-IV scores for the healthy siblings ranged from 85 to 121 (M = 
107.31, SD = 8.70) (see Table 12).  
Number of intrathecal chemotherapies (ITs).   
A one-tailed t-test on sibling pair difference scores was conducted with the factor being 
number of intrathecal chemotherapies, high (IT >20) and low (IT <19), and the dependent 
variable being intelligence as operationalized by the WISC-IV Full Scale IQ. The Full Scale IQ 
score combines the scores from all 10 subtests that assess intellectual functioning related to 
verbal comprehension, perceptional reasoning, working memory, and processing speed. A 
positive difference score indicates that the child with ALL performed better than his or her 
healthy sibling, while a negative difference score indicates the child with ALL performed more 
poorly than his or her healthy sibling. The t-test p-value for the factor IT was set at .005 (see 
Table 8) and fell short of significance when applying the Holmes-Bonferroni Correction, t (14) = 
1.798; p = .047, although the effect size was large (d = .89). The mean IQ difference score 
between children with ALL who received high IT and their healthy siblings was approximately 
minus nine points  (M = -8.71, SD = 10.22), whereas the mean difference score between children 
with ALL who received low IT and their healthy siblings was negligible (M = -0.44, SD = 8.20). 
Mean IQ for children with ALL who received high IT was 102.00 (SD = 9.39), vs. 110.71 (SD = 
6.34) for their healthy siblings.  
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Time off therapy (TOT).  
A one-tailed t-test on sibling pair difference scores was conducted with the factor being 
time off therapy high (TOT >5) and low (TOT <5), and the dependent variable being intelligence 
as operationalized by the WISC-IV Full Scale IQ (see Table 9). The t-test indicated no 
significant intelligence effects for the factor TOT, t (14) = .525, p = .304. The mean difference 
score between high TOT children with ALL and their healthy siblings (M = -5.22, SD = 11.51), 
versus the mean difference score between low TOT children with ALL and their healthy siblings 
(M = -2.57, SD = 7.59), indicated that IQ scores of children with ALL who were off therapy for 
varying periods of time were equivalent.   
Reading Composite 
The scores on the Wechsler Individual Achievement Test - Second Edition subtests 
(WIAT-II) measuring reading comprehension and pseudoword reading ranged from low average 
to high average. Children with ALL had reading composite scores ranging from 92 to 114 (M = 
107.96, SD = 9.76). Scores for the healthy sibling group ranged from 92 to 123 (M = 108.96, SD 
= 10.35).  See Tables 6 and 7 for participants’ individual scores for Reading Composite.  
Number of intrathecal chemotherapy (ITs). 
A one-tailed t-test on sibling pair difference scores was conducted with the factor being 
number of intrathecal chemotherapies, high (IT >20) and low (IT <19), and the dependent 
variable being reading as operationalized by the Reading Composite score of the WIAT-II. The 
reading composite score represents participants’ combined performance on the WIAT-II Reading 
Comprehension and Pseudoword subtests. The t-test indicated a significant reading effect for the 
factor IT, t (14) = 3.633, p <.001, and a large effect size (d=1.81) was noted (see Table 8) .  The 
mean difference score between children with ALL who received high IT was seven points lower 
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than their healthy siblings (M = -7.36, SD = 6.54), while the mean difference score for the  
children with ALL who received low IT was about four points higher than their siblings (M = 
3.94, SD = 5.89)  . Using the Holmes-Bonferroni Correction, these findings reach statistical 
significance.  
Time off therapy (TOT). 
A one-tailed t-test on sibling pair difference scores was conducted with the factor being 
time off therapy, high (TOT >5) and low (TOT <5), and the dependent variable being reading as 
operationalized by the Reading Composite score of the WIAT-II. The reading composite score 
represents subjects’ combined performance on the WIAT-II Reading Comprehension and 
Pseudoword subtests. The t-test indicated no significant reading effects for the factor TOT, t (14) 
= 2.077, p = .028, although the effect size was large (d=1.06) (see Table 9). The mean difference 
score between children with ALL and their healthy siblings (M = -4.44, SD = 8.16) indicated that 
children with ALL who were off therapy longer performed four points lower than their healthy 
siblings on the reading composite measure. Low TOT children with ALL scored three points 
above their healthy siblings (M = 3.43, SD = 6.56).  
Math Reasoning  
The scores on the Wechsler Individual Achievement Test - Second Edition (WIAT-II) 
testing math reasoning ranged from low average to superior. The scores of children with ALL 
ranged from 89 to 125 (M = 108.43, SD = 9.40) on math reasoning. Scores for the healthy sibling 
group ranged from 85 to 132 (M = 109.12, SD = 12.70). See Table 6 (children with ALL) and 
Table 7 (healthy siblings) for participants’ individual scores for math reasoning. 
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Number of intrathecal chemotherapies (ITs). 
A one-tailed t-test on sibling pair difference scores was conducted with the factor being 
number of intrathecal chemotherapies, high (IT >20) and low (IT <19), and the dependent 
variable being math reasoning as operationalized by the Math Reasoning Score of the WIAT-II. 
The t-test indicated significant math reasoning effects for the factor IT, t (14) = 3.079, p = .004, 
and a large effect size (d=1.61) was noted (see Table 8).   The mean difference score between 
children with ALL who received high IT was about nine points below their healthy siblings (M = 
-8.85, SD = 6.04), while children with ALL who received low IT performed five points higher 
than their healthy siblings (M = 5.22, SD = 11.46). Using the Holmes-Bonferroni Correction, 
these findings reach statistical significance.  
Time off therapy (TOT). 
A one-tailed t-test on sibling pair difference scores was conducted with the factor being 
time off therapy, high (TOT >5) and low (TOT <5), and the dependent variable being math 
reasoning as operationalized by the Math Reasoning Score of the WIAT-II. The t-test was not 
significant between the two groups for the factor TOT, t (14) = 2.791, p = .007, although the 
effect size was large (d=1.30) (see Table 9). The high TOT mean difference score indicated that 
children with ALL who were off therapy longer performed about seven points lower on the math 
measure than their healthy siblings (M = -6.67, SD = 6.09). The mean difference score of the low 
TOT children with ALL indicates they performed six points higher than their healthy siblings    
(M = -6.43, SD = 12.83).  
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Three-Minute Writing Sample 
The scores for the three-minute writing task ranged from borderline to high average. The 
scores of children with ALL ranged from 65 to 112 (M = 93.62, SD = 13.83) on the writing task. 
Scores for the sibling group ranged from 72 to 120 (M = 96.83, SD = 19.93).  
Number of Intrathecal chemotherapies (ITs). 
A one-tailed t-test on sibling pair difference scores was conducted with the factor being 
number of intrathecal chemotherapies, high (IT >20) and low (IT <19), and the dependent 
variable being writing as operationalized by the total words written. The t-test indicated no 
significant writing effects for the factor IT, t (14) = .406, p =.345 (see Table 8).  
Time off therapy (TOT). 
A one-tailed t-test on sibling pair difference scores was conducted with the factor being 
time off therapy, high (TOT >5) and low (TOT <5), and the dependent variable being writing as 
operationalized by the total words written. The t-test indicated no significant writing effects for 
the factor TOT, t (14) = -.185, p = .527 (see Table 9).  
Inattention 
The Test of Variable Attention – Omission composite scores (inattention) ranged from 
well below average to the average range for the participants in this study. The scores of children 
with ALL ranged from 83 to 110 (M = 97.01, SD = 14.08). Scores for the healthy sibling group 
ranged from well below average to the average range 41 to 105 (M = 83.31, SD = 22.87).  See 
Table 6 (children with ALL) and Table 7 (healthy siblings) for participants’ individual scores for 
inattention. 
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Number of intrathecal chemotherapies (ITs). 
A one-tailed t-test on sibling pair difference scores was conducted with the factor being 
number of intrathecal chemotherapies, high (IT >20) and low (IT <19), and the dependent 
variable being inattention as operationalized by the TOVA – Omission composite score 
(inattention). The t-test indicated no significant inattention effects for the factor IT, t (14) = 
1.198, p = .125, although the effect size was moderate (d = .62) (see Table 8).  The mean 
difference score between children with ALL who received high IT and their healthy siblings 
indicated that the siblings performed six points lower on this measure of inattention (M = 6.21, 
SD =  16.06).  The mean difference score between children with ALL who received low IT and 
their healthy siblings was about 20 points lower for the siblings (M = 19.52, SD = 25.65). 
Time off therapy (TOT). 
A one-tailed t-test on sibling pair difference scores was conducted with the factor being 
time off therapy, high (TOT >5) and low (TOT <5), and the dependent variable being inattention 
as operationalized by the TOVA– Omission composite score. The t-test indicated no significant 
inattention effects for the factor TOT, t (14) = .707, p = .246 (see Table 9). The mean difference 
score of high TOT children with ALL from their siblings indicated that children with ALL who 
were off therapy longer performed over one standard deviation better than their healthy siblings 
on the measure of inattention (M = 17.25, SD = 26.75).  In contrast, the mean difference score of 
low TOT children with ALL was nine points higher than their healthy siblings (M = 9.14, SD = 
15.92). 
Impulsivity  
The Test of Variable Attention Commission composite scores, which tested impulsivity, 
ranged from well below average to high average. The scores of children with ALL ranged from 
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60 to 111 (M = 92.31, SD = 17.84). Scores for the healthy siblings ranged from 52 to 111 (M = 
87.32, SD = 20.21). See Table 6 (children with ALL) and Table 7 (healthy siblings) for 
participants’ individual scores for impulsivity. 
Number of Intrathecal chemotherapies (ITs).  
A one-tailed t-test on sibling pair difference scores was conducted with the factor being 
number of intrathecal chemotherapies, high (IT >20) and low (IT <19), and the dependent 
variable being impulsivity as operationalized by the TOVA Commission composite score. The t-
test indicated no significant impulsivity effects for the factor IT, t (14) = 1.304, p = .107, 
although the effect size was moderate (d = .64) (see Table 8). The mean difference score between 
children with ALL who received high IT and their healthy siblings indicated that they performed 
similarly to their healthy siblings (M = -3.61, SD = 20.87).  Low IT children with ALL 
outperformed their healthy siblings by approximately 12 points (M = 11.67, SD = 24.86). 
Time off therapy (TOT). 
A one-tailed t-test on sibling pair difference scores was conducted with the factor being 
time off therapy, high (TOT >5) and low (TOT <5), and the dependent variable being 
impulsivity as operationalized by the TOVA Commission composite score (impulsivity). The t-
test indicated no significant impulsivity effects for the factor TOT, t (14) = -.415,  p = .342 (see 
Table 9). The mean difference score of the high TOT group was seven points (M = 7.22, SD = 
28.20), and the mean difference score of the low TOT group was two points (M = 2.11, SD = 
18.30), when compared to their healthy siblings.   
Processing Speed 
Scores for the Test of Variable Attention Response Time composite (TOVA) ranged from 
well below average to the superior range. The scores of children with ALL ranged from 48 to 
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121 (M = 95.37, SD = 24.07). Scores for the healthy siblings ranged from 56 to 117 (M = 92.40, 
SD = 20.19).  
Number of intrathecal chemotherapies (ITs). 
A one-tailed t-test on sibling pair difference scores was conducted with the factor being 
number of intrathecal chemotherapies, high (IT >20) and low (IT <19), and the dependent 
variable being processing speed as operationalized by the TOVA. The t-test indicated no 
significant processing speed differences for the factor IT, t (14) = .504, p = .311 (see Table 8).  
Time off therapy (TOT). 
 A one-tailed t-test on sibling pair difference scores was conducted with the factor being 
Time Off Therapy, high (TOT >5) and low (TOT <5), and the dependent variable being 
processing speed as operationalized by the TOVA Response Time Score. The t-test indicated no 
significant processing speed effects for the factor TOT, t (14) = .960, p =. 177 (see Table 9).  
Verbal Memory 
Participant’s scores ranged from below average to above average on the Combined List A 
1-5 of the California Verbal Learning Test for Children (CVLT). The scores of children with 
ALL ranged from 73 to 121 (M = 102.62, SD = 12.46). Scores for the healthy siblings ranged 
from 76 to 121 (M = 99.86, SD = 12.66). 
 Number of intrathecal chemotherapies (ITs).  
A one-tailed t-test on sibling pair difference scores was conducted with the factor being 
number of intrathecal chemotherapies, high (IT >20) and low (IT <19), and the dependent 
variable being verbal memory as operationalized by the CVLT combined List A 1-5. The t-test 
indicated no significant verbal memory effects for the factor IT, t (14) = .046; p = .481) (see 
Table 8).  
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Time off therapy (TOT).  
A one-tailed t-test on sibling pair difference scores was conducted with the factor being 
Time Off Therapy, high (TOT >5) and low (TOT <5), the dependent variable being verbal 
memory as operationalized by the CVLT  Lists A 1-5. The t-test indicated no significant verbal 
memory effects for the factor TOT, t (14) = -.018, p = .507 (see Table 9).  
Executive Functioning  
All but one subject’s scores were within average ranges on the Rey Osterrieth Complex 
Figure Test (RCFT) Copy Measure. Scores of children with ALL ranged from 90 to 104 (M = 
99.98, SD = 4.29). Scores for the healthy siblings ranged from 82 to 108 (M = 98.69, SD = 6.30).  
Number of intrathecal chemotherapies (ITs).  
A one-tailed t-test on sibling pair difference scores was conducted with the factor being 
number of intrathecal chemotherapies, high (IT >20) and low (IT <19), and the dependent 
variable being executive functioning as operationalized by the RCFT Initial copy score. The t-
test indicated no significant executive function effects for the factor IT, t (14) = .582; p = .285 
(see Table 8).  
Time off therapy (TOT).  
A one-tailed t-test on sibling pair difference scores was conducted with the factor being Time 
Off Therapy, high (TOT >5) and low (TOT <5), and the dependent variable being executive 
functioning as operationalized by the RCFT Initial copy score. The t-test indicated no significant 
executive functioning effects for the factor TOT, t (14) = .601, p = .279 (see Table 9).    
Parent Perception of Executive Functioning  
Participants’ scores ranged from below average to high average on the Behavioral Rating 
Index of Executive Functioning - Global Executive Composite (BRIEF). The scores of children 
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with ALL ranged from 84 to 130, (M = 100.32, SD = 17.10). Scores for the siblings ranged from 
84 to 133, (M = 103, SD = 17.20).  
Number of intrathecal chemotherapies (ITs).  
A one-tailed t-test on sibling pair difference scores was conducted with the factor being 
number of intrathecal chemotherapies, high (IT >20) and low (IT <19), and the dependent 
variable being parent perspective of executive functioning as operationalized by the BRIEF - 
Global Executive Function Composite, which consists of the BRIEF Inhibit, Initiate, and 
Monitor scores. The t-test for the factor IT indicated no significant executive functioning effects 
based on parent perspectives, t (12) = .392; p = .278 (see Table 8).  
Time off therapy (TOT).  
A one-tailed t-test on sibling pair difference scores was conducted with the factor being 
Time Off Therapy, high (TOT >5) and low (TOT <5), and the dependent vaariable being parent 
perspective of executive functioning as operationalized by the BRIEF. The t-test indicated no 
significant executive functioning effects of TOT, based on parent perspective, t (12) = .370, p = 
.337 (see Table 9).  
Post Hoc Analysis 
There are many limitations that threaten both the internal and external validity of this 
study.  Many of the issues stem from the small sample size. Despite best efforts to obtain a larger 
cohort, the sample size issue that is common with single site pediatric cancer studies occurred in 
this study as well. Therefore, interpretation of the findings need to be cautious and conservative.  
Moreover, interpretation of findings was hampered due to the  artificial division of 
participants into high and low groups.  To help understand the findings a post hoc correlation 
analysis examined the relationship between number of intrathecal chemotherapies and the 
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amount of time off therapy for the children with ALL. Results indicated a positive relationship 
between IT and TOT r(16) = .72.    
In addition it was noted that seven participants in the high IT group also were in the high 
TOT group, and seven in the low IT group also were in the low TOT group; this meant that data 
for these students were identical when analyzing high vs. low IT or TOT.  In contrast, the 
remaining two participants contributed unique variance in the analyses because they were 
“mixed”: in the low IT group but high TOT, These two mixed children may have 
disproportionately affected the findings as either their IT or TOT was unlike that of their other 
group members.  It could be argued that the analysis might have been done best by excluding 
these two families. In this case, the groups in all domains would be n = 7 for high IT and high 
TOT, and n = 7 for low IT and low TOT. 
To explore this point, post hoc analyses was conducted, without the two mixed pairs, for 
all domains that had a significant finding or moderate to large effect size in the original analyses. 
As in the original analysis, the t-test (n = 14) found significantly poorer reading composite (p = 
.005) and large effect size (d = 1.65) for the high IT (and high TOT) group, than for the low IT 
(and low TOT) group, when compared with their healthy siblings (p = .005).  Unlike the original 
analysis, the math reasoning effect for children with ALL missed significance (p = .007), though 
the effect size remained large (d = 1.52). The original analysis reported a large effect size for 
FSIQ, which in the post hoc analysis became a moderate effect size (d = .68).  The moderate 
effect sizes for inattention and impulsivity in the initial analysis did not hold up in the post hoc 
analyses.  Given these post hoc results, a conservative and cautious approach to interpretation of 
the results is warranted.  
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Summary 
This study examined the intellectual, academic, and neuropsychological outcomes of 
ALL treatment using a sibling-controlled design. Overall, the post therapy children with ALL 
and their healthy siblings performed in the average range for all the domains studied.  The only 
exception was for both inattention and impulsivity, where the healthy siblings in the low IT and 
high TOT groups scored below average. 
Despite the overall average performance of the children with ALL, children who had 
received high numbers of intrathecal chemotherapy treatments had significantly lower reading 
composite and math performance than the low IT ALL group, relative to their healthy siblings. 
The children with ALL in the high IT and high TOT groups demonstrated a large effect size for 
both the reading composite and math reasoning domains. Intelligence quotient showed a large 
effect size for high IT children with ALL, who scored lower than low IT children with ALL, 
when compared to their healthy siblings. Moderate effect size for inattention and impulsivity also 
related to the factor number of ITs, where low IT children with ALL outperformed their healthy 
siblings. Given that several of these findings did not hold up in the post hoc analyses, they 
should be interpreted with caution.  
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Chapter 5: Discussion 
Major Findings  
The current study’s findings replicate prior research demonstrating delays in IQ, reading, 
and math achievement for children who had been treated for ALL, although their performance 
was in the average range. The study supports findings (Brown et al., 1996; Brown et al., 1998; 
Espy et al., 2001; Lyer et al., 2016; Peterson et al., 2008; Reddick et al., 2006) that the relative 
delay experienced by children with ALL in these areas is related to high IT. There also is 
evidence in this study that the relative delay on reading composite and math reasoning is 
influenced by high TOT. In this study, low IT (19 or fewer ITs) and low TOT (under 5 years off 
therapy) were not related to any harmful effects on the participants’ cognitive, academic, or 
neuropsychological development.  
In summary, when compared to their siblings, children who received 20 or more ITs 
performed poorer on intelligence, reading, and math measures than those who received 19 or 
fewer intrathecal treatments. In addition those with five or more years off therapy were more 
discrepant from their siblings in reading and math reasoning than children with ALL who were 
off therapy fewer than five years. Because there was no baseline data available, it is impossible 
to know if the losses experienced by children with ALL are minor or major losses. These 
findings suggest that future research should explore in greater depth the particular elements of 
intelligence, reading, and math that are affected by ALL treatment, in order to take preventive 
and remedial action.  Despite treatment effects noted in this study, it is heartening that, after two 
and a half years of therapy that includes systemic chemotherapy, intrathecal chemotherapy, and a 
host of other treatments, post therapy children with ALL generally performed at expected levels 
for their ages on the study’s measures.  
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This study did not replicate findings of prior research that showed weaknesses in verbal 
memory, processing speed, attention, and executive functioning in children who had been treated 
for ALL. In addition, no weaknesses were found on factors that have seldom been explored in 
the ALL literature: writing prose, parent rating of executive functioning, and the role of 
impulsivity in poor attention. 
The findings of this study suggest that, where sample size is low, sibling difference 
scores might be a valuable method of analyzing the effects of treatment on post therapy children 
with ALL, and possibly other types of rare childhood medical conditions. Analyzing difference 
scores, one factor at a time, provides an alternative to the ANOVA when cell size is small, as is 
common in single site studies.  
The findings of this study also suggest that comparing the number of IT chemotherapies, 
and how these affect intelligence, achievement, and neuropsychological outcomes, is valuable in 
studying long term effects of ALL treatment where matching of treatment protocols is not 
possible.  The current study adopted Ashford et al.’s (2010) and Pui et al.’s (2003) method of 
using number of ITs to study the impact of high vs. low IT on children with ALL.   
Only six known studies (in addition to the current study) have used sibling control groups 
(Jansen et al., 2008; Kaemingk et al., 2004; Mitby et al., 2003; Reddick et al., 2006; Reeves et 
al., 2007; Rodgers et al., 2003). Of these studies, Jansen et al., Reddick et al., and Reeves et al. 
used a neurocognitive battery similar to that in the current study. The use of healthy sibling 
controls allowed this study to control for the family’s cancer experience, family genetics, and for 
demographics, such as SES and parental education level. It could not control, however, for age, 
gender and undiagnosed medical or psychosocial conditions. Due to this and other 
methodological issues in this study, any conclusions must be interpreted cautiously.  
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Domain Specific Findings 
Research has indicated that general IQ may be affected by higher cumulative doses of IT 
chemotherapy (Kingma et al., 2002; Ochs et al., 1991; Reddick et al., 2006). The current study 
found a similar impact on intellectual functioning when receiving 20 or more ITs. The current 
study did not find any effect on IQ when analyzing the number of years off therapy.  
Recent studies have found moderate reading decoding delays among children who have 
been treated for ALL (Campbell et al., 2007; Peterson et al., 2008; Reddick et al., 2006; Spiegler 
et al., 2006). Some studies have found reading comprehension delays as well, while others have 
not (Brown et al., 1998; Campbell et al., 2007; Espy et al., 2001; Waber et al., 2007). The 
findings from the current study support previous research demonstrating that a relative reading 
weakness, when compared to their healthy siblings, is not unusual for children with ALL who 
were treated with high IT and were five or more years off therapy. Perusal of the group means 
indicated that pseudoword reading was comparable across all groups, and that the significant 
findings for reading composite likely were due to weaker reading comprehension in high IT 
children with ALL; these children scored 12 points lower on the Reading Comprehension subtest 
than their healthy siblings. Similarly, the high TOT children with ALL underperformed their 
healthy siblings by about eight points. Low IT and low TOT children with ALL performed on 
both tasks very much like their healthy siblings.  Future research needs to explore which of these 
aspects of reading skill are most at risk, as both are critical to reading success.   
Similar to reading, the majority of studies of math achievement have shown math 
calculation delays in children treated for ALL (Brown et al., 1996; Carey et al., 2008; Espy et al., 
2001; Kaemingk et al., 2004; Reddick et al., 2006; Waber et al., 2007). The current study is one 
of only a few that utilized math reasoning rather than math calculations in the assessment battery. 
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The analyses demonstrated a relative weakness in math reasoning, when compared to their 
healthy siblings, for both the high IT and high TOT groups;  children with ALL scored 
approximately one-half SD below their healthy siblings in both cases. In contrast, the low IT and 
low TOT ALL groups performed somewhat stronger than their siblings. It is suggested that 
further research consider a mathematics-specific study that compares math calculation versus 
conceptual math ability, relative to number of ITs and time off therapy for survivors of childhood 
ALL.  
There were unexpected moderate effect size findings for inattention and impulsivity in 
the original analyses, with healthy siblings scoring worse than the children with ALL. When the 
post hoc analysis was conducted, however, these findings changed to a small effect size.  The 
effect of the two mixed families that switched in the analysis between the high and low groups, 
exemplifies the concern that with a small sample size even two family pairs can 
disproportionately affect findings.  Table 13 illustrates the number of times that individual 
families showed large variability in performance between the two siblings, again calling for a 
conservative approach to conclusions drawn from this study.  In addition to the above concerns, 
it should be noted that some of the sibling data in this small N study was not normal, therefore 
complicating interpretation. 
Despite caution in interpreting this study’s findings, the question of how the cancer 
experience effects siblings remains.  Reddick et al. (2006), one of three known studies of ALL 
chemotherapy effects to use a matched sibling control group to study attention, found attentional 
issues with the healthy siblings.   
   The researcher contacted Dr. Reddick from St. Jude’s Hospital to request unpublished 
data from his study regarding healthy sibling attention. In an email correspondence, Dr. Reddick 
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(2/18/2010) shared unpublished healthy sibling data, which demonstrated attention issues on the 
Conner’s Continuous Performance Test (CPT) (see Table 14).  According to the Connors CPT, 
T-scores in the low 60s are mildly atypical and T-scores of 70 or higher are considered markedly 
atypical. Reddick et al. reported extremely atypical omission scores for sibling controls on the 
Conner’s CPT (t = 80.75 + 19.199), while performance of children with ALL was “at risk” (t = 
62.9 + 8.7).   
A review of Sharpe and Rossiter’s (2002) meta-analysis of 51 studies across different 
childhood medical conditions found that cognitive development scores were lower for siblings 
who had a brother or sister with a chronic medical condition than for siblings who had healthy 
brothers or sisters. Research on siblings of children with cancer almost always focuses on social 
or emotional aspects of having a sibling with a life-threatening illness (e.g., post-traumatic stress 
disorder symptoms) and not on cognitive consequences (Alderfer, Labay, & Kazak, 2003; 
Campbell et al., 2009; Kazak et al., 2004). For example, Alderfer et al. (2003) found that 49% of 
siblings exhibited mild post-traumatic stress disorders (PTSD), and an additional 32% exhibited 
moderate to severe levels of PTSD. This data suggests that a sizable percentage of siblings of 
childhood ALL survivors may be at risk for experiencing emotional and/or other disorders 
related to the shared childhood cancer experience and that this should continue to be explored. 
Limitations  
The small, self- selected convenience sample, coupled with the large number of 
dependent variables measured and the artificial grouping into high or low IT and TOT groups 
caused analysis concerns in this study.  Control for sex, age, SES, age at diagnosis of ALL, 
treatment protocol, and other factors in this study was not possible.  Moreover, this was an 
underpowered study that also had issues of normality on some of the measures.  Despite findings 
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that replicate other, (e.g., Brown et al., 1996, Brown et al., 1998; Kaemingk et al., 2004), this 
study’s results need to be interpreted cautiously due to the many methodological constraints.   
As is the case with many single-site research studies of children with cancer, the small 
sample size left the current study vulnerable to Type II error: failing to find significance due to 
limits with power (Campbell et al. 2007). Sample size required this study to utilize composite 
scores, which then limited the ability to distinguish patterns across the composites’ subtests. For 
example, although reading composite results were significant, performance on the pseudoword 
(decoding) task could not be compared statistically with reading comprehension performance. 
The current study’s limited sample size prevented a more processing-focused approach to 
understanding intelligence, achievement, and neuropsychological functioning with this 
population of learners.  
Unfortunately, the present study had only two female participants with ALL. Numerous 
studies have found females with ALL to be more susceptible to cognitive late effects of 
treatment (Brown et al., 1998; Butler et al., 2002; Mulhern et al., 2004), but this couldn’t be 
explored further in this study.   
Another limitation is that this study focused on math reasoning only. Most previous 
research has focused on math calculation.  Studies with post therapy children with ALL that 
focus on both math concepts and math calculations would be essential to better understand the 
impact of the cancer experience on math skills.  
Design issues are common in this field of work, as so few children are diagnosed with 
childhood cancer (Moore, 2005). Children at a single hospital will typically be treated on 
different protocols and a number of variables will impact the amount of treatment they receive 
(e.g., age, weight, gender, disease progression at time of diagnosis). All of these factors influence 
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the treatment regimen and ultimately potential outcomes. For example, all participants with ALL 
in the current study received methotrexate via IT, which puts them into a higher risk category for 
late effects than had non-methotrexate protocols been followed. However, the sample size 
prevented analysis of the data by age, chemotherapy protocol, and the other relevant variables 
mentioned above. 
Grouping participants into high and low IT groups also brings up the issue of how much 
the significant findings for high vs. low IT were related to the anesthesia necessary to administer 
treatment, rather than to the chemotherapy itself. At each IT treatment, the patient with ALL 
receives general anesthesia.  Although the effects of anesthesia in children are not well known, 
Wilder et al. (2009) found that when children under the age of four are exposed to multiple 
anesthetics (two or more), there is a statistically significant increase in learning disabilities later 
in life. Similarly, Flick et al. (2011) found that multiple anesthetics increased the likelihood for 
learning disabilities, even when the analysis ruled out confounding health related issues that may 
themselves negatively impact learning. Ing et al. (2012) found that children under the age of 
three who were exposed to anesthesia were more likely than their healthy peers to experience 
significant delays in receptive language, expressive language, and cognition. This raises the 
question of whether some portion of detrimental effects typically experienced by children with 
ALL may be due to factors related not just to the intrathecal treatment but to other aspects of the 
treatment experience as well, such as anesthesia effects.  
 Another factor this study was unable to account for was the effect of direct instructional 
time and number of days absent from school, both of which could affect the performance of 
children with ALL. Also, considering this was a single-site study at a treating institution with a 
robust educational intervention program, it is unclear how these educational services influenced 
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the outcome of this study. It is estimated that approximately 60 of the 230 children’s hospitals in 
the U.S. have some level of dedicated educational support staff, making this treatment center 
somewhat unusual with its high level of support (two full-time educational liaisons). Much still 
needs to be learned about the impact of these programs, and whether participants, such as in this 
study, experience fewer academic and cognitive late effects of treatment due to the intensive 
educational and emotional support they receive during- and post-treatment.  
Seven children with ALL (44%) in this study took advantage of hospital educational 
outreach services, and nine of the children with (56%) agreed to have the hospital set up a 504 
Plan or Individual Educational Program (IEP) while on treatment. Students with 504 Plans 
received extra time on tests, extra time passing in the hall, and other accommodations, such as 
note-takers when absent from school. Students with IEPs were given the same accommodations, 
but also benefitted from additional direct instruction by educators at home or in the hospital. This 
support may have mitigated the development of more serious delays. Unfortunately, a record 
review did not reveal any further information that could be used to interpret the relative strengths 
and weaknesses of the children treated for ALL.  
Implications of Findings 
This study has five important findings to contribute to the study of effects of treatments 
on children with ALL:  
1) In general, post therapy children with ALL are performing within average ranges in 
every domain assessed, which implies that treatment protocols are causing less harm in the 
realms of cognition, learning, and information processing than in the past. In fact, the average 
performance of children with ALL in the low IT group surpassed their healthy siblings in reading 
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composite, math reasoning, attention measures, processing speed, verbal memory, and executive 
functioning (copying task).  
2) This study’s findings replicated neurocognitive relative weaknesses for post therapy 
children with ALL who received high IT on intelligence, reading composite, and mathematics 
reasoning tasks.  
3) This study explored the impact of a five-year time off therapy split to investigate if and 
when declines in skills such as reading and math reasoning become evident. The results from this 
study show that late effects in reading and math reasoning are particularly problematic five or 
more years off therapy. 
4) This study demonstrated that number of ITs may be a possible substitute when 
cumulative dosage information is not a practical option, due to small sample size and multiple 
treatment protocols.  
5) This study utilized sibling difference scores as the data for analysis when studying 
childhood ALL. The use of difference scores proved promising for maximizing power, given the 
small sample size. 
 Continued study of the cognitive, academic, and neuropsychological effects of childhood 
ALL treatments is important in order to identify and find ways to mitigate delays that become 
apparent over time.  With more knowledge about the treatment factors that are particularly 
deleterious, treatment protocols can be modified and educational interventions introduced to 
prevent predicted neurocognitive weaknesses. 
Suggestions for Future Research 
The findings of this study suggest there is still much to learn and understand about the 
cognitive, academic, and neuropsychological characteristics and needs of children treated for 
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acute lymphocytic leukemia. The continued participation of healthy sibling cohorts in 
neurocognitive studies also is useful in shedding light on the needs of healthy siblings who have 
lived through the cancer experience.  Of course, the use of a healthy sibling has its limitations as 
each sibling and each home experience is unique.  Therefore, in addition to healthy sibling 
groups, researchers should continue to use other comparison groups of children with chronic 
conditions or survivors of childhood cancers that do not require cognitively threatening therapy. 
These controls allow the researcher to differentiate the psychosocial issues, as well as treatment 
protocol and disease effects, on learning and development.  The need for larger sample sizes 
when possible is evident. 
When possible, future researchers should consider gathering samples from multiple 
childhood cancer treatment institutions in order to obtain an adequate number of subjects to 
control for the variables that could not be controlled in this study. When small sample sizes are 
unavoidable, it is recommended that researchers choose a more narrow focus of study so that 
specific areas of cognitive functioning may be evaluated in more depth. This study suggests that 
the many aspects of reading decoding, comprehension, math calculation and math reasoning be 
explored in depth by using diagnostic assessment batteries. The more researchers can discover 
about the weaknesses contributing to academic delays, the more able educators will be to design 
interventions that target the weaknesses and accelerate success. When there are no diagnostic 
batteries to measure a certain skill, it is recommended that multiple measures of the same 
construct be administered (e.g., executive functioning, attention) to tap its multiple components 
to the fullest extent possible.  In addition, more research is needed to better understand what 
impact there is on affective functioning such as resilience and risk taking, and how these factors 
impact the academic functioning of children with ALL.  Finally, while it is difficult to do, 
  67 
 
 
research in the field would be clearer if baseline data could be collected at the time of ALL 
diagnosis, or as soon after treatment begins as is practical. 
Given recent MRI results pointing to structural brain differences associated with ALL 
treatment, future childhood ALL research may find it useful to use FMRI to compare brain 
activation during specific tasks. Studies also could consider including in the assessment battery a 
computerized continuous processing test (CPT) to measure attentional issues.  
While a high amount of IT chemotherapy is typically considered a negative predictor in reading 
and math areas, so is more time off therapy.  In addition to accounting for the number of ITs and 
cumulative dosage that a child receives, future studies should continue to explore the role of 
TOT, which suggests that relatively negative effects become more apparent with time, especially 
five or more years post-treatment.  What remains unexplored is if the relationship between 
longer time off therapy and difficulty in learning tasks relates to the more challenging academic 
expectations in the upper elementary grades or to the loss of instructional time when basic skills 
were being developed. Given the high inter-correlation between IT and TOT among post therapy 
children with ALL, future research should attempt to tease out how much of the treatment effects 
reported in the literature are accounted for by IT, and how much by the more difficult school 
curriculum as TOT increases.  Specifically, studies with larger sample sizes could examine the 
interaction between time off therapy and ITs in relation to task demands that get harder. In larger 
studies, control for the age when the child became ill also is recommended.   
The cancer experience stretches a family’s time, emotional, and financial resources 
(Labay & Walco, 2004; Steinglass, 1998). Prior research has documented the social-emotional 
effect of cancer treatment on patients, and recent research has begun to focus on long-term 
psychosocial effects on healthy siblings without cancer, primarily in the form of PTSD issues. 
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Alderfer et al. (2003; 2010), Campbell et al. (2009), Kazak et al. (2004), and Long, Marsland, 
and Alderfer (2013) have found that the cancer experience has a considerable emotional and 
social toll on the healthy siblings as well as the child with ALL. This body of work emphasizes 
the need to provide increased support early on, not only to children with cancer, but also to their 
families in general, and to the siblings specifically. The need to more systematically measure 
whether early psychoeducational support helps to minimize relatively negative effects on the 
healthy siblings is very important.  
 Future studies at a national level also should compare the outcomes from treating 
hospitals that have educational services for children with ALL vs. those that do not. Canada 
recently moved to standardizing psychosocial care at all 17 of the pediatric cancer centers 
throughout the country. Therefore, if a child in Canada is diagnosed with cancer, the child will 
receive the same level of educational service regardless of SES, geography, or treating 
institution. This includes standardizing the educational supports childhood cancer patients 
receive while on treatment and after treatment is completed. This allows Canada to conduct 
national studies focused on various aspects of psychosocial and educational care, including 
educational and cognitive effects of childhood cancers. This type of national study is not possible 
in the U.S. at this time.  
Peterson et al. (2008) concluded that a national standardized neuropsychological battery 
needs to be created and implemented across studies of ALL outcomes in hopes of being able to 
better track outcomes and impediments in the educational experience of children with ALL. This 
in turn would allow educators to be more proactive regarding the learning needs of children with 
ALL, even after treatment has terminated. There is a move among hospital-based educators in 
the U.S. to begin to address these concerns (Irwin & Elam, 2011).  
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The current study indicates that high numbers of IT treatments appear to be problematic 
for reading and mathematics skills, and affect intellectual functioning. In addition, late effects of 
ALL treatment are more evident five years or more off therapy, than fewer years off therapy.  
Much more research needs to be conducted on the issues discussed above. Fortunately for 
children with ALL, lower number of IT treatments continues to be the trend in treating the 
disease, which seems to result in fewer decrements in achievement. Moreover, the TOT literature 
implies the need to take preventive educational measures, in the hopes of stemming predictable 
late effects of treatment. 
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Tables 
Table 1 
 
Sibling Pair Demographic Data 
  
Sibling 
Pair No. 
 
Age at 
Time of 
Testing 
Number 
of  ITs 
Time Off Therapy 
Years -Months-Days 
Gender SES Race 
 
Family 1 
Survivor 
Sibling 
 
10-7 
12-10 
 
19 
 
 
4 -10 -19 
 
Male 
Male 
 
Upper 
Middle 
 
White 
 
Family 2 
Survivor 
Sibling 
 
9-4 
10-10 
 
16 
 
3 - 3-22 
 
Male 
Female 
 
Middle 
 
White 
 
Family 3 
Survivor 
Sibling 
 
10-9 
13-3 
 
15 
 
 
4 - 2 -27 
 
Male 
Female 
 
Upper 
Middle 
 
White 
 
Family 4 
Survivor 
Sibling 
 
11-0 
13-11 
 
16 
 
4 - 1 – 28 
 
Male 
Female 
 
Upper 
Middle 
 
White 
 
Family 5 
Survivor 
Sibling 
 
10-7 
8-5 
 
18 
 
3 - 10 – 16 
 
Male 
Male 
 
Upper 
Middle 
 
White 
 
Family 6 
Survivor 
Sibling 
 
12-6 
10-8 
 
16 
 
2 - 10 - 11 
 
Male 
Female 
 
Upper 
Middle 
 
White 
 
Family 7 
Survivor 
Sibling 
 
11-7 
8-0 
 
16 
 
2  - 9  - 8 
 
Male 
Female 
 
Middle 
 
White 
 
Family 8 
Survivor 
Sibling 
 
  11-10 
13-3 
 
19 
 
5  -  9  -  0 
 
Male 
Male 
 
Lower 
Middle 
 
White 
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Sibling 
Pair No. 
 
Age at 
Time of 
Testing 
Number 
of  ITs 
Time Off Therapy 
Years -Months-Days 
Gender SES Race 
 
Family 9 
Survivor 
Sibling 
 
10-4 
  8-0 
17 
  
7  - 0 - 21 
 
Male 
Female 
 
Lower 
Middle 
 
White 
 
Family 10 
Survivor 
Sibling 
 
14-9 
11-9 
 
20 
 
7 - 11 – 3 
 
Male 
Female 
 
Upper 
Middle 
 
White 
 
Family 11 
Survivor 
Sibling 
 
12-8 
11-0 
 
22 
 
6 - 1 – 25 
 
Female 
Male 
 
Middle 
 
Hispanic 
 
Family 12 
Survivor 
Sibling 
 
13-9 
12-0 
 
22 
 
6-– 9 - 19 
 
Male 
Female 
 
Middle 
 
White 
 
Family 13 
Survivor 
Sibling 
 
14-0 
12-2 
 
20 
 
7 - 7 – 0 
 
Male 
Female 
 
Upper 
Middle 
 
White 
 
Family 14 
Survivor 
Sibling 
 
12-7 
11-0 
 
22 
 
6 - 1 – 15 
 
Male 
Female 
 
Upper 
Middle 
 
White 
 
Family 15 
Survivor 
Sibling 
 
14-4 
11-7 
 
22 
 
6 - 1 – 26 
 
Female 
Male 
 
Low 
Middle 
 
White 
 
Family 16 
Survivor 
Sibling 
 
 
12-6 
14-7 
 
21 
 
8 – 1 - 20 
 
Male 
Male 
 
Middle 
 
White 
 
Note. SES = Socioeconomic Status; ITs = Number of Intrathecal chemotherapies. 
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Table 2 
 
Scatter Plot of Participant IT and TOT Groups 
 
 
 
Note. ITs = number of intrathecal chemotherapies; TOT=time off therapy; a = 3 subject data 
points (all completed therapy within three days of each other). 
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Table 3 
 
Descriptive Statistics for Children with ALL and Healthy Sibling Groups 
  
                                                   Children with ALL            Siblings 
     n = 16   n = 16       
Domain       
& Measure               M (SD)             M (SD)         
 
Intelligence Quotient: 
WISC-IV Full Scale IQ  103.25(8.73)  107.31(8.70) 
 
Reading Composite:  
WIAT-II    107.96(9.76)  108.96(10.35) 
 
Mathematics: 
Math Reasoning   108.43(9.40)  109.12(12.70)  
 
Writing: Three-Minute 
Writing Sample      93.62(13.83)    96.83(19.93)  
 
Inattention: 
TOVA Omission      97.01(14.08)    83.31(22.87) 
 
Impulsivity: 
TOVA Commission     92.31(17.84)    87.32(20.21)  
 
Processing Speed: TOVA 
Response Time Composite   95.37(24.07)    92.40(20.19)  
   
Verbal Memory: 
CVLT List A 1-5   102.62(12.46)    99.86(12.66)  
 
Executive Function: 
RCFT – Copy       99.98(4.29)    98.69(6.30)  
 
Executive Function: 
BRIEF – Global    100.32(17.10)  103.00(17.20) 
Executive Composite   n=14   n=14 
 
 
Note. M = mean; SD = standard deviation; n = sample size; WISC-IV = Wechsler Intelligence 
Scale for Children - Fourth Edition; IQ = intelligence quotient; WIAT-II = Wechsler Individual 
Achievement Test - Second Addition; TOVA = Test of Variable Attention; CVLT = California 
Verbal Learning Test; RCFT = Rey-Osterrieth Complex Figure Test; BRIEF = Behavior Rating 
Inventory of Executive Functioning. 
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Table 4 
 
Descriptive Statistics for High/Low IT and High/Low TOT Groups of Post Treatment for 
Children with ALL  
 
 
 High IT Low IT High TOT Low TOT 
 (>20) (<19) (>5 years) (<5 years) 
 n = 7 n = 9 n = 9 n = 7 
Domain 
& Measure 
M (SD) M (SD) M (SD) M (SD) 
Intelligence Quotient: 
WISC-IV Full Scale IQ 
102.00(9.39) 104.22(8.61) 101.66(10.59) 105.28(5.67) 
Reading Composite: 
WIAT-II 
107.85(8.92) 108.05(6.72) 107.00(6.76) 
109.21(9.33) 
 
Mathematics: 
Math Reasoning 
106.57(10.32) 109.44(8.96) 105.33(9.60) 112.42(8.05) 
Writing: Three-Minute 
Writing Sample 
95.81(16.56) 93.07(16.11) 95.04(10.08) 91.79(18.31) 
Inattention: 
TOVA Omission 
95.71(9.25) 98.02(9.15) 98.41(9.70) 95.21(8.28) 
Impulsivity: 
TOVA Commission 
88.92(18.42) 94.94(12.03) 91.55(17.40) 93.28(12.18) 
Processing Speed: TOVA 
Response Time Composite 
97.25(24.49) 93.91(22.80) 100.22(22.02) 89.14(23.93) 
Verbal Memory: 
CVLT List A 1-5 
105.28(8.15) 101.44(15.29) 102.88(13.71) 103.42(11.74) 
Executive Function: 
RCFT – Copy 
101.46(1.83) 98.82(5.35) 101.51(1.89) 98.01(5.77) 
Executive Function: 
BRIEF – Global  
Executive Composite 
106.99(28.85) 
 
(n = 6) 
95.77(22.98) 
 
(n = 8) 
109.04(20.67) 
 
(n = 8) 
 
92.12(22.18) 
 
(n = 6) 
Note. IT = Intrathecal chemotherapies; TOT = Time off therapy; M = mean; SD = standard 
deviation; n = sample size; WISC-IV = Wechsler Intelligence Scale for Children - Fourth 
Edition; IQ = intelligence quotient; WIAT-II = Wechsler Individual Achievement Test - Second 
Addition; TOVA = Test of Variable Attention; CVLT = California Verbal Learning Test; RCFT 
= Rey-Osterrieth Complex Figure Test; BRIEF = Behavior Rating Inventory of Executive 
Functioning. 
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Table 5 
 
Descriptive Statistics for High/Low IT and High/Low TOT Groups of Healthy Siblings  
 
 
 High IT Low IT High TOT Low TOT 
 (>20)  (<19) (>5 years) (<5 years)   
 n = 7 n = 9 n = 9 n = 7 
Domain &  
Measure 
M (SD)              M (SD)      M (SD) M (SD)      
Intelligence Quotient: 
WISC-IV Full Scale IQ 
110.71(6.34)  104.66(9.68)  106.88(10.28)  107.85(6.89) 
Reading Composite:  
WIAT-II 
115.21(4.09)  104.11(9.80)  111.44(8.46)  105.78(10.42) 
Mathematics: 
Math Reasoning 
115.42(9.08)  104.22(13.35)  112.00(10.45)  105.99(15.13) 
Writing: Three-Minute  
Writing Sample 
 94.33(11.43)   97.63(12.52)   97.60(14.78)  95.85(13.86) 
Inattention: 
TOVA Omission 
 89.50(14.12)   78.50(20.21)   81.16(21.29)   86.07(14.26) 
Impulsivity: 
TOVA Commission 
 92.53(8.36)   83.27(21.81)   84.33(17.93)   91.17(17.34) 
Processing Speed: 
TOVA Response Time 
Composite 
 91.25(24.99)   93.30(11.25)   92.86(22.02)   91.82(12.20) 
Verbal Memory: 
CVLT List A 1-5 
101.85(8.82)   98.44(15.37)   98.77(9.78)  101.42(16.38) 
Executive Function: 
RCFT – Copy 
100.94(3.73)   96.95(7.55)  100.51(5.47)   96.36(7.01) 
Executive Function: 
BRIEF – Global 
Executive Composite 
 
106.83(14.85)  
 
 (n = 6) 
100.12(15.03)  
 
(n = 8) 
109.85(15.74)  
 
(n = 8) 
 96.14(10.76) 
 
(n = 6) 
 
Note.  IT = Intrathecal chemotherapies; TOT = Time off therapy; M = mean; SD = standard 
deviation; n = sample size; WISC-IV = Wechsler Intelligence Scale for Children - Fourth 
Edition; IQ = intelligence quotient; WIAT-II = Wechsler Individual Achievement Test - Second 
Addition; TOVA = Test of Variable Attention; CVLT = California Verbal Learning Test; RCFT 
= Rey-Osterrieth Complex Figure Test; BRIEF = Behavior Rating Inventory of Executive 
Functioning.
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Table 6 
 
Children with ALL: Mean Scores on Significant, Large, and Medium Effect Size Measures 
 
Family No.:     
(Groups) 
FSIQ Reading 
Composite 
Math 
Reasoning 
Inattention Impulsivity 
1        
(Low IT Low TOT) 
105     99.5 100   97   97 
2  
(High IT High TOT) 
112 112 113   83   94 
3 
(Low IT High TOT) 
  87   98   96 110   60 
4 
(High IT High TOT) 
  98 112 103   97 101 
5  
(Low IT Low TOT) 
108    113.5 125  96 108 
6 
(High IT High TOT) 
116 113 123 103   94 
7 
(Low IT High TOT) 
106 110 106 106   91 
8 
(Low IT Low TOT) 
105 116 109   84   81 
9 
(Low IT Low TOT) 
105   112.5 111 100   98 
10 
(High IT High TOT) 
  92  106.5 104 101   70 
11  
(Low IT Low TOT) 
115       116 118  99   80 
12 
(High IT High TOT) 
  92    93.5 107 100 108 
13  
(Low IT Low TOT) 
  96   92.5 108   85   84 
14  
(Low IT Low TOT) 
103 114.5 116 107 108 
15 
(High IT High TOT)  
  99      109 107   83   71 
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Family No.:     
(Groups) 
FSIQ Reading 
Composite 
Math 
Reasoning 
Inattention Impulsivity 
16  
(High IT High TOT 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
105 109   89 105 111 
 
Note. FSIQ = Full Scale Intelligence Quotient; IT = Intrathecal chemotherapies; TOT = Time off 
therapy. 
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Table 7 
 
Healthy Siblings:  Mean Scores on Significant, Large, and Medium Effect Size Measures 
 
Family No.:     
(Groups) 
FSIQ Reading 
Composite 
Math 
Reasoning 
Inattention Impulsivity 
1        
(Low IT Low TOT) 
  96   95   85   93   79 
2  
(High IT High TOT) 
108 114 115   71   94 
3 
(Low IT High TOT) 
  85     94.5   98   41   60 
4 
(High IT High TOT) 
110 115 116   97   70 
5  
(Low IT Low TOT) 
116 122 123   97   96 
6 
(High IT High TOT) 
121 123 132 105   82 
7 
(Low IT High TOT) 
102 102 102   63   52 
8 
(Low IT Low TOT) 
114 110.5 110   71   62 
9 
(Low IT Low TOT) 
112 111.5 126   63   82 
10 
(High IT High TOT) 
112 113.5 106   99   86 
11  
(Low IT Low TOT) 
108 107.5   96 103 104 
12 
(High IT High TOT) 
110 113.5 112   82   85 
13  
(Low IT Low TOT) 
104   91.5   95   95 104 
14  
(Low IT Low TOT) 
105 102.5 103   87 111 
15 
(High IT High TOT)
   
114 110 121 101   98 
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Family No.:     
(Groups) 
FSIQ Reading 
Composite 
Math 
Reasoning 
Inattention Impulsivity 
16  
(High IT High TOT) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
1 117.5 106   73 103 
 
Note. FSIQ = Full Scale Intelligence Quotient; IT = Intrathecal chemotherapies; TOT=Time off 
therapy. 
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Table 8 
 
Difference Score Statistical Analyses for Numbers of Intrathecal Chemotherapy Treatments 
 
   High IT Low IT  
   (>20)  (<19) 
   n = 7  n = 9 
Domain    
& Measure             M  (SD)           M  (SD)      t-test p value Cohen’s d 
 
Intelligence 
Quotient: WISC-IV 
Full Scale IQ  -8.71(10.22)  -.44(8.20) 1.798 .047  d=.89  
              
Reading Composite:  
WIAT-II  -7.36(6.54)  3.94(5.89) 3.633 .001*  d=1.81 
           
Mathematics: 
Math Reasoning -8.85(6.04)  5.22(11.46) 3.079 .004*  d=1.61 
              
Writing: 
Three-Minute  
Writing Sample  1.48(16.72) -4.56(17.35)   .406 .345  d=.21 
 
Inattention: 
TOVA Omission  6.21(16.06)   19.52(25.65) 1.198 .125  d=.62 
           
Impulsivity: 
TOVA Commission -3.61(20.87)   11.67(24.86) 1.304 .107  d=.64 
           
Processing Speed: 
TOVA Response Time 
Composite   6.00(16.54)    .61(24.17)  .504 .311  d=.26 
 
Verbal Memory: 
CVLT List A 1-5  3.43(11.98)  3.00(22.02)  .046 .481  d=.02 
 
Executive Function: 
RCFT – Copy   0.52(3.73)  1.87(10.94)  .582 .285  d=.29 
 
Executive Function: 
BRIEF – Global   0.16(10.51) -4.35(15.79)  .392 .278  d=.15 
Executive Composite  (n = 6) (n = 8) 
 
 
Note. M = mean difference score between sibling pairs based on a M of 100; SD = standard 
deviation; a SD of 15; n = sample size; IT = Intrathecal chemotherapies; WISC-IV = Wechsler 
Intelligence Scale for Children - Fourth Edition; IQ = intelligence quotient; WIAT-II = Wechsler 
Individual Achievement Test - Second Addition; TOVA = Test of Variable Attention; CVLT = 
California Verbal Learning Test; RCFT = Rey-Osterrieth Complex Figure Test; BRIEF = Behavior 
Rating Inventory of Executive Functioning. * p = .005, one tailed t-test. 
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Table 9 
 
Difference Score Statistical Analyses for Time off Therapy 
 
   High TOT Low TOT  
   (>5 years) (<5 years) 
   n = 9  n = 7 
Domain:  
Measure             M (SD)            M (SD)      t-test p value Cohen’s d 
 
Intelligence 
Quotient: WISC-IV 
Full Scale IQ  -5.22(11.51) -2.57(7.59)  .525   .304  d=.27 
   
Reading Composite:  
WIAT-II  -4.44(8.16)  3.43(6.56)      2.077   .028  d=1.06 
           
Mathematics: 
Math Reasoning -6.67(6.09)   6.43(12.83)    2.791   .007  d=1.30 
           
Writing: 
Three-Minute  
Writing Sample -2.56(10.02) -4.06(19.91)  -.185   .572  d=.09   
        
Inattentiveness: 
TOVA Omission 17.25(26.75)   9.14 (15.92)   .707   .246  d=.37 
 
Impulsivity: 
TOVA Commission 7.22(28.20)   2.11(18.30)  -.415   .342  d=.22 
 
Processing Speed: 
TOVA Response Time 
Composite  7.36(14.89) -2.68(26.63)   .960   .177  d=.47 
 
Verbal Memory: 
CVLT List A 1-5 4.11(15.00)  2.00(22.06)  -.018   .507  d=.11 
 
Executive Function: 
RCFT – Copy  1.00(6.32)   1.65(10.99)   .601   .279  d=.30 
 
Executive Function: 
BRIEF – Global  -0.81(9.94) -4.02(17.02)   .370   .337  d=.10 
Executive Composite  (n = 8) (n = 6) 
 
 
Note. M = mean difference score between sibling pairs based on a M of 100; SD = standard 
deviation; a SD of 15; n = sample size; IT = Intrathecal chemotherapies; WISC-IV = Wechsler 
Intelligence Scale for Children - Fourth Edition; IQ = intelligence quotient; WIAT-II = Wechsler 
Individual Achievement Test - Second Addition; TOVA = Test of Variable Attention; CVLT = 
California Verbal Learning Test; RCFT = Rey-Osterrieth Complex Figure Test; BRIEF = Behavior 
Rating Inventory of Executive Functioning. *p = .005, one tailed t-test. 
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Table 10 
 
Wechsler Intelligence Scale for Children - Fourth Edition Subscale Scores  
 
 High IT Low IT High TOT Low TOT 
 (>20)  (<19) (>5 years) (<5 years)   
 n = 7 n = 9 n = 9 n = 7 
Intelligence 
Quotient 
Subscale 
M (SD)              M (SD)      M (SD) M (SD)      
 
Children with ALL 
    
Verbal 
Comprehension 
Index 
105(13.85)  103.11(14.78)  104.11(17.93)  103.71(12.49) 
Perceptual 
Reasoning Index 
103.71(11.14)  106.66(8.17)  103.33(9.97)  108(8.22) 
Working Memory 
Index 
100.42(4.75)  103.22(10.98)  103.57(12.66)  106.28(7.93) 
Processing Speed 
Index 
 
   
  93.28(8.15)   
    
  98(12.88)   93.88(8.84)   98.57(12.77) 
Siblings     
Verbal 
Comprehension 
Index 
114.28(7.06)  107.33(12.40)  111.44(9.34)  109(12.90) 
Perceptual 
Reasoning Index 
108.57(4.96) 
  
105.55(7.87)  106(6.83) 108(6.95) 
Working Memory 
Index 
106.28(7.93)  101.44(14.54)  102.77(11.88)  104.57(13.03) 
Processing Speed 
Index 
 
100.57(20.18)   
       
  96.11(9.30)   97.11(18.77)   99.28(7.91) 
 
Note. M = mean; SD = standard deviation; n = sample size.   
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Table 11 
 
Children with ALL: WISC-IV Subscale Individual Scores 
 
Family 
No. 
WISC-IV    
   . V.C 
          WISC-IV        
.              P.R 
      WISC-IV                                                               
.           W.M 
WISC IV
P.S. 
WISC IV 
FSIQ 
1 95 100 120 106 105 
2 110 117 102 103 112 
3 81 96 102 83 87 
4 106 98 102 80 98 
5 112 117 91 94 108 
6 124 121 102 94 116 
7 121 108 102 109 114 
8 124 110 94 75 105 
9 102 104 102 106 105 
10 98 94 94 88 92 
11 110 121 120 91 115 
12 87 92 107 94 92 
13 87 102 91 112 96 
14 96 102 107 106 103 
15 91 102 102 103 99 
 
16 
 
 
119 
 
102 
 
94 
 
91 
 
105 
 
Note. WISC IV V.C. = Wechsler Intelligence Scale for Children - Fourth Edition, Verbal 
Comprehension Index; WISC P.R. = Wechsler Intelligence Scale for Children - Fourth Edition, 
Perceptual Reasoning Index; WISC W.M. = Wechsler Intelligence Scale for Children - Fourth 
Edition, Working Memory Index; WISC P.S. = Wechsler Intelligence Scale for Children - Fourth 
Edition, Processing Speed Index; WISC FSIQ = Wechsler Intelligence Scale for Children - 
Fourth Edition, Full Scale Intelligence Quotient. 
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Table 12 
 
Healthy Siblings: WISC-IV Subscale Individual Scores  
 
                                     WISC-IV       WISC-IV             WISC-IV          WISC-IV        WISC-IV 
    
Family 
No.        V.C. P.R.  W.M. P.S.  FSIQ 
IV1 96 102 88 100 96 
2 112 115 94 97 108 
3 93 94 77 85 85 
4 114 104 107 103 110 
5 128 112 102 100 116 
6 124 115 116 109 121 
7 110 100 104 85 102 
8 119 115 107 97 114 
9 119 106 126 83 112 
10 106 108 107 115 112 
11 104 98 116 106 108 
12 110 104 116 100 110 
13 95 117 94 106 104 
14 102 106 99 103 105 
15 110 110 102 121 114 
16 124 104 102 59 100 
 
 
Note. WISC IV V.C. = Wechsler Intelligence Scale for Children - Fourth Edition, Verbal 
Comprehension Index; WISC P.R. = Wechsler Intelligence Scale for Children - Fourth Edition, 
Perceptual Reasoning Index; WISC W.M. = Wechsler Intelligence Scale for Children - Fourth 
Edition, Working Memory Index; WISC P.S. = Wechsler Intelligence Scale for Children - Fourth 
Edition, Processing Speed Index; WISC FSIQ = Wechsler Intelligence Scale for Children - 
Fourth Edition, Full Scale Intelligence Quotient.  
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Table 13 
 
Sibling Pair Large Variability Data 
 
Dependent  Family Pair Number     Family Pair Number   
Variable:  Child with ALL Negative Skew Child with ALL Positive Skew 
 
 
Full Scale IQ (#13)   -20   high IT & high TOT   (#9)     12     low IT & high TOT 
(#14)   -18   high IT & high TOT 
(#15)   -15   high IT & high TOT 
 
Reading   (#14)   -20   high IT & high TOT (#15)     12     high IT & high TOT 
Composite 
 
Math     (#3)   -15    low IT & low TOT   (#1)     15     low IT & low TOT 
Reasoning  (#16)   -17    high IT & high TOT   (#4)     22     low IT & low TOT 
 
Total     (#1)   -21    low IT & low TOT   (#6)     20     high IT & high TOT 
Words   (#13)   -19    high IT & high TOT 
Written    (#4)   -36    low IT & low TOT 
 
TOVA  (#16)   -18    high IT & high TOT   (#8)     69     low IT & high TOT 
Inattention         (#9)     43     low IT & high TOT 
       (#14)     18     high IT & high TOT 
(#15)     20     high IT & high TOT 
 
TOVA  (#11)    -31   high IT & high TOT   (#1)     17     low IT & low TOT 
Impulsivity  (#13)   -16    high IT & high TOT   (#8)     50     low IT & high TOT 
    (#4)   -25    low IT & low TOT   (#9)     40     low IT & high TOT 
  (#5)   -20    low IT & low TOT   (#7)     18     low IT & low TOT 
(#15)   -26    high IT & high TOT   (#3)     15     low IT & low TOT 
     (#14)     23     high IT & low TOT 
 
TOVA    (#1)   -22    low IT & low TOT (#10)     35     high IT & high TOT 
Response    (#2)   -34    low IT & low TOT     (#9)     18     low IT & high TOT 
Time     (#7)   -31    low IT & low TOT   (#4)     35     low IT & low TOT 
       (#14)     19     high IT & high TOT 
  (#5)     17     low IT & low TOT 
 
CVLT List A   (#7)   -13   low IT & low TOT   (#9)     19     low IT & high TOT 
  (#3)     15     low IT & low TOT 
  (#5)     23     low IT & low TOT 
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Dependent  Family Pair Number     Family Pair Number   
Variable:  Survivor Negative Skew  Survivor Positive Skew 
 
RCFT – Copy (#11)   -25   high IT & high TOT   (#1)     20     low IT & low TOT 
  (#9)   -24   low IT & high TOT   (#8)     22     low IT & high TOT 
  (#7)   -30   low IT & low TOT   (#3)     29     low IT & low TOT 
(#13)   -16   high IT & high TOT (#15)     34     high IT & low TOT 
(#16)   -20   high IT & high TOT 
 
BRIEF Parent  (#11)    -13  high IT & high TOT (#15)     51     high IT & high TOT 
Report  
 
 
Note. IT = Intrathecal chemotherapies; TOT = Time off therapy. 
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Table 14 
 
Healthy Sibling and Post Therapy Children with ALL Attention Data: Reddick  (2006) 
Attention    Siblings (n = 33)    Survivors (n = 84) 
     T Score   T Score 
      
Omissions (percentile)                  80.75 ± 19.199*  62.9 ± 8.7b* 
D (attentiveness)a                 57.47 ± 9.06   57.6 ± 10.4b 
 
a=attentiveness was measured as the time difference between the stimulus and non-stimulus item on the screen 
(how often and how quickly the participant clicks the response button, when the target is not on the screen) 
 
b=Statistically significant differences from test norms superscript symbols (P < 0.01) as analyzed in the   
2006 study 
*Scores of 60 or above indicate abnormally high inattention or impulsivity 
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Appendix B 
Consent Forms Hackensack University Medical Center 
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Appendix C 
Consent Forms Syracuse University 
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Institutional Review Board Syracuse University 
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Teaching, 25(3/4) 177-196. 
Gordon, D. S., & Ghosh, C. (2013). Building Community Partnerships with Adults with 
Disabilities: A Case Study Using Narrative Literacy as a Conduit for Shared Learning. 
Learning Communities Research and Practice, 1(3), Article 8. Available at 
http://washingtoncenter.evergreen.edu/lcrpjournal/vol1/iss3/8 
Book Chapter 
Gordon, D.S. (under review 2015). Using Civil Rights and Disability Rights History to 
Encourage Social Equity. In the forthcoming book: Beyond Bystanders: Educational 
Leadership for a Humane Culture in a Globalizing Reality. 
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Gordon, D.S. (2009). Case study: Online learning as a way to access and involve new 
communities.  In W. B. Crow and H. Din, Unbound By Place or Time: Museums and 
Online Learning, American Association of Museums Press, 109-113. 
 
Other Selcted Reports and Publications 
Gordon, D.S. and Armstrong, D. Pediatric Cancer - Insights, Challenges, Strategies & Resources 
(2011).  Educational materials development for the Leukemia and Lymphoma Society's 
continuing education training programs for oncology nurses and social 
workers.  Available 
at http://www.lls.org/researchershealthcareprofessionals/ce/cepast/051911_pediatric. 
Gordon, D.S., contributor and reviewer (2013).  Learning and Living with Cancer: Advocating 
for Your Child’s Educational Needs. Leukemia and Lymphoma Society.  Training and 
resource material for the Society’s continuing education program, “Staying Connected: 
Facilitating the Learning Experiences During & After Cancer Treatment.” Available at 
http://www.lls.org/content/nationalcontent/resourcecenter/freeeducationmaterials/childho
odbloodcancer/pdf/learninglivingwithcancer.pdf. 
Labay, L, and Gordon, D.S. (2007).  The Use of Genetic Technology in Pediatric Oncology. The 
Research Connection. The Joint Psychosocial and Nursing Advisory Group to the New 
Jersey Commission on Cancer Research. 1, 4-6.Available at 
http://www.state.nj.us/health/ccr/documents/2007number1.pdf. 
Donnangelo, S. & Gordon, D. (2007).  Robot connects high school “teachers” with hospitalized 
learners.  The NYIT Educational Enterprise Zone Videoconferencing News, 18. 
Donnangelo, S. & Gordon, D. (2007).  Student with chronic illness stays connected with 
classmates.  The NYIT Educational Enterprise Zone Videoconferencing News, 19. 
Gordon, D.S. and Finley, S.M. (2002).  Advocacy through education: Tomorrows Children’s 
Institute Educational Outreach Service. New Jersey Commission on Cancer 
Research  The Research Connection, Spring 2002, 4-6. 
 
 (December 1, 2020) WABC News NYC 
“Using Video conferencing to keep youth connected to learning” 
 
PRESENTATIONS 
Refereed National and International Conferences 
Gordon, D., (April 10, 2015). Bringing the Museum to You: Utilizing Virtual Technology to 
Increase Motivation and Educational Engagement Council for Exceptional Children 
International Conference. San Diego, CA. 
Gordon, D., (2014). Bone Marrow Transplant Information Network International Conference. 
“Managing Learning & School Issues After a Pediatric Transplant.” East Rutherford, NJ 
September 12, 2014. 
Grimmet, K., and Gordon, D.S., (2014). Counsel for Exceptional Children. “Experiencing 
Willowbrook: Using Virtual Faculty to Connect Educators to the Past and the NEW 
Present.” Philadelphia, PA. April 11, 2014 
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Lemke, R., Gordon, D.S., and Griffin, K., (2014). Association for Pediatric Hematology 
Oncology Educational Specialists. “Models of Hospital Education: Next Steps for 
improving Quality and Sustainability” Columbus, OH May 2, 2014 
Gordon, D.S., (2012). Association of Pediatric Hematology Oncology Educational Specialists 
(APHOES). “The Sibling Perspective: Possible Attentional Effects on siblings of 
Childhood Cancer Survivors”. Akron, OH. May 2, 2012. 
The Technology Haystack: How to Know Which Technology to Use When with Children with 
Chronic Health Conditions. Association for the Education of Children with Medical 
Needs (AECMN) National Conference Portland, OR. November 9, 2012. 
Gordon, D.S., (2011). Association for the Education of Children with Medical Needs (AECMN) 
National Convention. “Educational Outcomes of Digital Based Learning for Children 
with Cancer.”.  Atlanta, GA, October 18, 2011. 
Fitting a Square Peg in a Round Hole: An Acquired Learning Disability February, 2002 Learning 
Disabilities Association International Conference. Denver, CO.  
Complex Issues Courageous Lives: Living and Learning at College with Asperger’s Syndrome 
March 3-6, 2001 American College Personnel Association (ACPA) Conference. Boston, 
MA.  
Academic and Social Effects for Survivors of Childhood Cancer at College, March 3-6, 2001 
American College Personnel Association (ACPA) Conference.  Boston, MA.  
 
Invited National Presentations 
Gordon, D.S., (2014). Keynote: Bringing the Museum to You: Utilizing Virtual Technology to 
Increase Motivation and Educational Engagement. At the Empowering Students with 
Physical & Health Impairments conference, California Association for Physical and 
Health Impairments. San Diego, CA, February 14-15. 
Gordon, D.S., (2012). Keynote: I Deal to Ideal: An Inside Out Approach to Education. MSTI 
Education Conference St. Luke’s Hospital, Boise, ID, September 22, 2011. 
Gordon, D.S., (2012). Keynote: Transition, Access, and Equity: Avoiding Transitional Pitfalls to 
Achieve Life’s Goals. MSTI Education Conference. St. Luke’s Hospital, Boise, ID 
September 22, 2011. 
 
Regional Presentations 
Leukemia and Lymphoma Society Psychosocial Trainer/Speaker: 
Gordon, D.S. (2014). Staying Connected: Facilitating the Learning Experiences During & After 
Cancer Treatment.  Training for the Leukemia and Lymphoma Society, West Chester, 
NY, April 24. 
Gordon, D.S. (2014). Staying Connected: Facilitating the Learning Experiences During & After 
Cancer Treatment.  Training for the Leukemia and Lymphoma Society, NY, NY, May 
22. 
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Gordon, D.S. (2012). Staying Connected: Facilitating the Learning Experiences During & After 
Cancer Treatment.  Training for the Leukemia and Lymphoma Society, West Chester, 
NY, February 16. 
Gordon, D.S. (2012). Choosing the Right College: An Educational Program for Survivors of 
Childhood Cancer.  Training for the Leukemia and Lymphoma Society, West Islip, NY 
March 30.  
Gordon, D.S. (2002-2010). Welcome Back: Facilitating the Return to School for Children with 
Cancer. Multiple presentations, typically 2-6 times a year, for Leukemia Lymphoma 
Society, Make A Wish Foundation, New Jersey’s School Counselor’s Conference, New 
Jersey Commission on Cancer Research (NJCCR), and the New Jersey Office of Cancer 
Control regarding the educational needs of children with life threatening illnesses. 
Additional Regional Presentations: 
Gordon, D.S. (2014). Supporting Special Needs Students. The Staten Island Reading Association 
Annual Literacy Symposium, Staten Island, NY, October 28. 
Gordon, D.S. (2012). How to Incorporate Technology as a Home Instruction Teacher in NYC. 
NYC DOE Hospital & Home Instruction Inservice Day. May 5. Staten Island Home 
Instruction. 
DeMoss, K, Fitzgerald, J., Gordon, D.S., and Preskill, S. (2012). The Right to Education. Panel 
presentation as part of Constitution Day. Wagner College, Staten Island, NY, September 
17.   
Gordon, D.S. (2012). Building Strong Community Partnerships in the FYP. Faculty Presentation 
at Wagner College, Staten Island, NY, November 14. 
Gordon, D.S. (2008). Grand Rounds, Educating Students with Chronic Health Conditions: Old 
Problems New Solutions. Newark Beth Israel Hospital, Newark, NJ, October 17. 
Gordon, D.S. (2002). From Classrooms to Cafeterias: A School Re-entry Program for Children 
with Chronic Illness. Presentation for the National Association of School Psychologists 
National Conference. Chicago, IL, March 1. 
Gordon, D.S. (2001). School and Work: What the Primary Physician Should Know. Sickle Cell 
Disease in 2001: Insights for Pediatric Health Care Providers. Conference.  Hackensack, 
NJ, June 6 
Gordon, D.S. (2001). Navigating the Educational System. Children with Cancer Go Back to 
School. Stony Brook University Hospital and Medical Center, NY, NY April 5. 
Gordon, D.S. (2000). Working with Preservice Teachers with Disabilities Panel discussion 
member to the New York State Department of Education committee on Teacher 
Preparation and Preservice Teacher Standards. Albany, NY, March 31 
 
RESEARCH PROJECTS AND GRANTS 
Wagner College 2014 
New York Community Trust ($10,000). Reaching Learners with Special Needs through 21st 
Century Technology Skills.  This program provides a series of learning goals that allow special 
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needs students to take risks, socialize, and engage in collaborative conversations to strengthen 
their digital media skills. In a format of three modules structured with technology teaching time 
and socialization time to promote social and emotional learning, Wagner College undergraduate 
and graduate students will assist in implementing the workshops.  
 
Robinson Fellowship ($2,500). An Investigation of the Implicit and Explicit Components of 
Democratic Engagement Taught Through Not-for-profit Educational Programs. 
 
Virtual Visits Science Labs with New York Hall of science ($100,000). The goal of this pilot 
program is to allow these students to get the science lab experiences they need virtually and still 
graduate on time with a Regents Diploma. Wagner College Portion ($10,000). 
 
HIVE NYC Grant with New York Hall of Science ($150,000). Air Casting for Middle School 
Students. Wagner College portion ($9,000). 
 
Silverman Family Foundation Grant with New York Hall of Science for virtual educational 
programming for hospital and homebound children ($10,000). Through work with Living 
Through Learning Foundation. 
 
Wagner College 2013 
HIVE NYC Grant with Parsons New School for Design ($100,000). gadgITERATION is a series 
of hands-on, entry-level design workshops that encourage students’ creative and artistic 
engagement with technology. Wagner College portion ($6,200). 
 
HIVE NYC Grant with New York Hall of Science ($150,000). Air Casting for Middle School 
Students. Wagner College portion ($9,000). 
 
Silverman Family Foundation Grant with New York Hall of Science for virtual educational 
programming for hospital and homebound children ($10,000). Through work with Living 
Through Learning Foundation 
 
Survivor Vision Foundation Research Grant for educational technology use by hospital teachers 
Pilot study to direct creation of a phone application for hospital and home instruction teachers 
($10,000). 
 
MEDIA REPORTS  
Lore, D. (2014, April 27). Wagner partners with Lifestyles for the Disabled. Staten Island 
Advance. Available at 
http://www.silive.com/news/index.ssf/2014/04/in_our_schools_wagner_college.html. 
 
Lore, D. (2014, July 22) Wagner College hosts scholars from Obama's Young African Leaders 
initiative. Staten Island Advance. Available at 
http://www.silive.com/northshore/index.ssf/2014/07/wagner_college_hosts_group_fro.html. 
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SERVICE  
National 
 
Founder and Executive Director, The Living Through Learning Foundation. 2008 – Present.  
www.livingthroughlearning.org,  
 
Reviewer & Advisory Board Member, 2014-15. Handbook of Research on Effective 
Communication in Culturally Diverse Classrooms, Frumkin, R. and Gonzalez, K, eds. 
Advances in Higher Education and Professional Development (AHEPD).  Forthcoming 
2015-16.  
 
President Elect, Division for Physical Health and Multiple Disabilities, Council for Exceptional 
Children (CEC), 2013-14. 
o Review and approve all presentation for national CEC conference 
o Organize and run all Executive board meetings 
o Set national division agenda for 2015  
o Collaborate with all committee chairs including journal editor, newsletter editor, 
membership committee, by-laws committee, and special topics committees 
 
Past President of Association of Pediatric Hematology Oncology Educational Specialists, 
(2009 – 2012) 
o Chaired Nominating Committee 
o Provided counsel to current president and other board members 
o Continue to provide leadership during national conference 
 
Joint Committee member for Association of Pediatric Hematology Oncology Educational 
Specialists and Association for the Education of Children with Medical Needs (2014 – 
Present)  
o One of seven individuals selected to provide recommendations to both organizations 
around complex and sensitive issues such as joint conferences, joint legislative agendas, 
and possible merger of the two organizations 
 
Reviewer & Advisory Board Member, 2011. Controlling Complexities: Understanding the 
Structures of Questions. Hardt, M. eds. Skill Plan.  2011.  
 
Regional/Local 
 
Provided test design & item design theory in-services for New World Prep Charter School 
 
Co-ran the Collect, Construct, Change (C3) project with New World Prep Charter School 
which aimed to: (1) equip youth with skills, knowledge, and tools to record, interpret, 
and communicate air quality information; (2) furnish youth with learning experiences 
that encourage them to engage with their environment, participate in community life, 
and understand why science is important in solving real-world problems; and (3) 
provide meaningful air quality information to the public and policy makers.   
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College 
Academic Review Committee (2012 – 2014) 
Intermediate Learning Community Member (2013 – 2014) 
First Year Program Member (2011, 2012, & 2014) 
Advisor for new student organization, Exceeding the Expectations, focused on raising 
disability awareness. (2014) 
Lead Educator for one week in the Young African Leaders Institute (Summer, 2014) 
2014 Diversity Action Council Award recipient 
 
Department 
Member, NCATE accreditation preparation team (2011-2012) 
Lead, Council for Exceptional Children (CEC) Specialty Program Association Accreditation 
Reports, grades 1-6 & 7-12 (2011-12) 
Lead, Council for Exceptional Children (CEC) Specialty Program Association Accreditation 
Reports, grades birth through 2 (2013-14) 
Lead, student support, both individual and group, for certification exam preparation for the 
Students with Disabilities CST Exam (2011-present)   
Departmental advisement beyond assigned advisees (2011-present). Entrance and exit 
interviews for undergraduate and graduate students, non-education students with an 
interest in psychosocial employment (psychology, social work, child life therapy, 
educational specialists) in hospital settings. 
 
 
    
Professional Associations   
 
Association of Pediatric Hematology Oncology Educational Specialists (APHOES). President 
(2009 – 2012) & Founding Member (2005 – Present) 
Association for the Education of Children with Medical Needs (AECMN). Member, Advocacy 
Committee (2008 – Present) 
Council For Exceptional Children (CEC) (2006-present) 
 
